



## DNA SEQUENCE-BASED HLA TYPING METHOD

### Technical Field

The present invention relates to a process for determining genotypes of highly polymorphic systems, such as the major histocompatibility complex of humans, including Class I and Class II HLA genes. Specifically, the method of the present invention involves amplifying the alleles carried by any given individual at a gene locus or loci of interest by polymerase chain reaction with conserved and non-conserved oligonucleotide primers. The polymerase chain reaction products are directly sequenced followed by evaluation of the resulting nucleic acid ladders to determine the genotype of sample nucleic acid.

### Background of the Invention

The major histocompatibility complex (MHC) includes the human leukocyte antigens (HLA) gene complex which is located on the short arm of human chromosome six. This region encodes cell-surface proteins which regulate the cell-cell interactions of the immune response. The various HLA Class I loci encode the HLA antigens, 44,000 dalton polypeptides which associate with B-2 microglobulin at the cell surface. The Class I molecules are involved in the recognition of target cells by cytotoxic T lymphocytes. HLA Class II loci encode cell surface heterodimers, composed of proteins of 29,000 and 34,000 daltons, respectively. These Class II molecules are also involved in the recognition of target cells by helper T lymphocytes.

The HLA-A, HLA-B, and HLA-C loci of the HLA Class I region as well as the HLA-DRB, HLA-DQB, HLA-DQA, HLA-DPB and HLA-DPA loci of the HLA Class II region exhibit an extremely high degree of polymorphism. The WHO nomenclature committee for factors of the HLA system

[Marsh and Bodmer, *Immunogenetics*, 31:131 (1990)]

designated 25 alleles of HLA-A (HLA-A-0101, A-0201, etc.), 32 alleles of HLA-B, and 11 alleles of HLA-C, 43

HLA-DRB alleles, 13 HLA-DOB alleles, 8 HLA-DQA alleles, 5 HLA-DPA alleles and 19 HLA-DPB alleles. Since this high degree of polymorphism is thought to relate to the function of the HLA molecules, much effort has gone into determining its molecular basis and the functional implications of its polymorphisms (i.e., in transplantation). With the cloning of certain HLA genes this effort has extended to the DNA level.

The Class II genes of the HLA-D region on the short arm of human chromosome six constitute one of the most polymorphic genetic systems known [Bach, *Immunol. Today*, 6:89 (1985)]. The HLA Class II molecules (DR, DQ and DP) are heterodimeric glycoproteins composed of two non-covalently associated chains (alpha and beta) which serve as restricting elements in nominal antigen presentation in the context of self [Zinkernagel and Doherty, *Nature*, 248:701 (1974)] or as foreign antigens in alloresponses [Bach and Van Rood, *N. Engl. J. Med.*, 295:806 (1976)].

Allelic polymorphism of the HLA-D region encoded specificities can be determined by serological methods for phenotyping, mixed lymphocyte cultures using homozygous typing cells, primed lymphocyte testing, determination of restriction fragment length polymorphisms and, more recently, oligotyping [Bach, *supra* (1985); Bidwell, *Immunol. Today*, 9:18 (1988); Tiercy et al., *Proc. Natl. Acad. Sci. USA*, 85:198 (1988)]. Present efforts focus largely on the development of molecular approaches to typing, such as RT-PCR and oligotyping [Bidwell, *supra* (1988); Tiercy et al., *supra* (1988); Erlich and Bugawan, in *PCR Techniques*, H. A. Erlich, ed., Stockton Press, New York (1989)].

3

The cloning and sequencing of several HLA-DR, DQ, and -DP alleles has revealed that their amino acid polymorphisms are located in hypervariable regions of their N-terminal domains, encoded by the second exon of DRB1, DRB3/4/5, DQA1 and DQB1, DPB1 and DPB1 genes [Marsh and Bodmer, *supra* (1990); Todd et al., *Nature*, 322:599 (1987)]. This information has allowed the design of allele-specific oligonucleotides which can be used in the characterization of the known HLA Class II polymorphisms by means of their hybridization to DNA on a solid support (oligomer typing) or for sequencing [Triary et al., *supra* (1988); Erlich and Bugawan, *supra*, (1989); Todd et al., *supra* (1987); Saiki et al., *Science*, 230:1350 (1985); Mullis and Faloona, *Methods Enzymol.*, 155:335 (1987); Saiki et al., *Nature*, 324:163 (1986); Scharf et al., *Science*, 233:1076 (1986); Gyllenstein and Erlich, *Proc. Natl. Acad. Sci. USA*, 85:7652 (1988)]. Oligonucleotide typing, although rapid, requires the use of a rather large number of oligonucleotides for each locus and cannot detect previously unidentified sequence polymorphisms, likely to exist in non-Caucasian populations; further, the approach may not be easily applicable to and may not be practical for the analysis of Class I polymorphisms.

Direct sequencing of single-stranded DNA generated by PCR using allele-specific oligonucleotides has been successfully used to examine polymorphism at DQA1 locus [Gyllenstein and Erlich, *supra* (1988)]. Application of this approach to DRB genes is, however, problematic due to the strong sequence homology among DRB1, DRB3, DRB4 and DRB5 genes and the presence of up to four different versions of each of these genes in most individuals (isotypic complexity). The very complex ladders generated by direct sequencing make this present process impractical for accurate and rapid determination of HLA types. Thus, direct sequencing of HLA-PCR products has been limited to previous knowledge of the HLA types

4

carried by a given individual and as such is not suitable for routine HLA typing [Bach, *supra* (1985); Bidwell, *supra* (1988); Tiercy et al., *supra* (1988); Erlich and Bugawan, *supra* (1989)].

Currently, HLA typing is routinely done in connection with many medical procedures, e.g., organ transplantation. Rejection of organ grafts is believed to be diminished if the HLA alleles of donor and recipient are identical. The numerous alleles of HLA genes in the population also make HLA typing useful for paternity testing. However, the currently available techniques are incapable of differentiating among all of the polymorphisms associated with the alleles at class I and Class II HLA loci. Other drawbacks to current HLA typing are the availability of standard sera necessary to conduct serological tests, the speed of obtaining test results (i.e., MLC takes 5-7 days), and that only the already known HLA types, but not new polymorphisms, are detected by these techniques. In the case of tissue typing in organ transplants and in relatively high volume genetic evaluations, such as paternity testing, the length of time associated with current HLA typing techniques causes unnecessary delay and the results may not be highly accurate.

Accordingly, there is a need for a method to determine genomic information in highly polymorphic systems, such as the HLA gene complex, that addresses the limitations imposed by previous methods. That is, in the case of the HLA gene complex, a system that is capable of determining the nucleotide sequences of the genes carried by any given individual without the need to have previous knowledge of his or her HLA types as defined by other methods. Furthermore, the invention avoids the use of oligonucleotides specific for each known allele. The technique we present is rapid, requires the use of only a small number of oligonucleotide primers, and can readily detect new

5

polymorphisms by means of their hybridization to DNA on a solid support (oligomer typing) or for sequencing [Triary et al., *supra* (1988); Erlich and Bugawan, *supra*, (1989); Todd et al., *supra* (1987); Saiki et al., *Science*, 230:1350 (1985); Mullis and Faloona, *Methods Enzymol.*, 155:335 (1987); Saiki et al., *Nature*, 324:163 (1986); Scharf et al., *Science*, 233:1076 (1986); Gyllenstein and Erlich, *Proc. Natl. Acad. Sci. USA*, 85:7652 (1988)]. Oligonucleotide typing, although rapid, requires the use of a rather large number of oligonucleotides for each locus and cannot detect previously unidentified sequence polymorphisms, likely to exist in non-Caucasian populations; further, the approach may not be easily applicable to and may not be practical for the analysis of Class I polymorphisms.

Direct sequencing of single-stranded DNA generated by PCR using allele-specific oligonucleotides has been successfully used to examine polymorphism at DQA1 locus [Gyllenstein and Erlich, *supra* (1988)]. Application of this approach to DRB genes is, however, problematic due to the strong sequence homology among DRB1, DRB3, DRB4 and DRB5 genes and the presence of up to four different versions of each of these genes in most individuals (isotypic complexity). The very complex ladders generated by direct sequencing make this present process impractical for accurate and rapid determination of HLA types. Thus, direct sequencing of HLA-PCR products has been limited to previous knowledge of the HLA types

10

carried by a given individual and as such is not suitable for routine HLA typing [Bach, *supra* (1985); Bidwell, *supra* (1988); Tiercy et al., *supra* (1988); Erlich and Bugawan, *supra* (1989)].

Currently, HLA typing is routinely done in connection with many medical procedures, e.g., organ transplantation. Rejection of organ grafts is believed to be diminished if the HLA alleles of donor and recipient are identical. The numerous alleles of HLA genes in the population also make HLA typing useful for paternity testing. However, the currently available techniques are incapable of differentiating among all of the polymorphisms associated with the alleles at class I and Class II HLA loci. Other drawbacks to current HLA typing are the availability of standard sera necessary to conduct serological tests, the speed of obtaining test results (i.e., MLC takes 5-7 days), and that only the already known HLA types, but not new polymorphisms, are detected by these techniques. In the case of tissue typing in organ transplants and in relatively high volume genetic evaluations, such as paternity testing, the length of time associated with current HLA typing techniques causes unnecessary delay and the results may not be highly accurate.

Accordingly, there is a need for a method to determine genomic information in highly polymorphic systems, such as the HLA gene complex, that addresses the limitations imposed by previous methods. That is, in the case of the HLA gene complex, a system that is capable of determining the nucleotide sequences of the genes carried by any given individual without the need to have previous knowledge of his or her HLA types as defined by other methods. Furthermore, the invention avoids the use of oligonucleotides specific for each known allele. The technique we present is rapid, requires the use of only a small number of oligonucleotide primers, and can readily detect new

15

polymorphisms by means of their hybridization to DNA on a solid support (oligomer typing) or for sequencing [Triary et al., *supra* (1988); Erlich and Bugawan, *supra*, (1989); Todd et al., *supra* (1987); Saiki et al., *Science*, 230:1350 (1985); Mullis and Faloona, *Methods Enzymol.*, 155:335 (1987); Saiki et al., *Nature*, 324:163 (1986); Scharf et al., *Science*, 233:1076 (1986); Gyllenstein and Erlich, *Proc. Natl. Acad. Sci. USA*, 85:7652 (1988)]. Oligonucleotide typing, although rapid, requires the use of a rather large number of oligonucleotides for each locus and cannot detect previously unidentified sequence polymorphisms, likely to exist in non-Caucasian populations; further, the approach may not be easily applicable to and may not be practical for the analysis of Class I polymorphisms.

Direct sequencing of single-stranded DNA generated by PCR using allele-specific oligonucleotides has been successfully used to examine polymorphism at DQA1 locus [Gyllenstein and Erlich, *supra* (1988)]. Application of this approach to DRB genes is, however, problematic due to the strong sequence homology among DRB1, DRB3, DRB4 and DRB5 genes and the presence of up to four different versions of each of these genes in most individuals (isotypic complexity). The very complex ladders generated by direct sequencing make this present process impractical for accurate and rapid determination of HLA types. Thus, direct sequencing of HLA-PCR products has been limited to previous knowledge of the HLA types

20

carried by a given individual and as such is not suitable for routine HLA typing [Bach, *supra* (1985); Bidwell, *supra* (1988); Tiercy et al., *supra* (1988); Erlich and Bugawan, *supra* (1989)].

Currently, HLA typing is routinely done in connection with many medical procedures, e.g., organ transplantation. Rejection of organ grafts is believed to be diminished if the HLA alleles of donor and recipient are identical. The numerous alleles of HLA genes in the population also make HLA typing useful for paternity testing. However, the currently available techniques are incapable of differentiating among all of the polymorphisms associated with the alleles at class I and Class II HLA loci. Other drawbacks to current HLA typing are the availability of standard sera necessary to conduct serological tests, the speed of obtaining test results (i.e., MLC takes 5-7 days), and that only the already known HLA types, but not new polymorphisms, are detected by these techniques. In the case of tissue typing in organ transplants and in relatively high volume genetic evaluations, such as paternity testing, the length of time associated with current HLA typing techniques causes unnecessary delay and the results may not be highly accurate.

Accordingly, there is a need for a method to determine genomic information in highly polymorphic systems, such as the HLA gene complex, that addresses the limitations imposed by previous methods. That is, in the case of the HLA gene complex, a system that is capable of determining the nucleotide sequences of the genes carried by any given individual without the need to have previous knowledge of his or her HLA types as defined by other methods. Furthermore, the invention avoids the use of oligonucleotides specific for each known allele. The technique we present is rapid, requires the use of only a small number of oligonucleotide primers, and can readily detect new

25

polymorphisms by means of their hybridization to DNA on a solid support (oligomer typing) or for sequencing [Triary et al., *supra* (1988); Erlich and Bugawan, *supra*, (1989); Todd et al., *supra* (1987); Saiki et al., *Science*, 230:1350 (1985); Mullis and Faloona, *Methods Enzymol.*, 155:335 (1987); Saiki et al., *Nature*, 324:163 (1986); Scharf et al., *Science*, 233:1076 (1986); Gyllenstein and Erlich, *Proc. Natl. Acad. Sci. USA*, 85:7652 (1988)]. Oligonucleotide typing, although rapid, requires the use of a rather large number of oligonucleotides for each locus and cannot detect previously unidentified sequence polymorphisms, likely to exist in non-Caucasian populations; further, the approach may not be easily applicable to and may not be practical for the analysis of Class I polymorphisms.

Direct sequencing of single-stranded DNA generated by PCR using allele-specific oligonucleotides has been successfully used to examine polymorphism at DQA1 locus [Gyllenstein and Erlich, *supra* (1988)]. Application of this approach to DRB genes is, however, problematic due to the strong sequence homology among DRB1, DRB3, DRB4 and DRB5 genes and the presence of up to four different versions of each of these genes in most individuals (isotypic complexity). The very complex ladders generated by direct sequencing make this present process impractical for accurate and rapid determination of HLA types. Thus, direct sequencing of HLA-PCR products has been limited to previous knowledge of the HLA types

30

carried by a given individual and as such is not suitable for routine HLA typing [Bach, *supra* (1985); Bidwell, *supra* (1988); Tiercy et al., *supra* (1988); Erlich and Bugawan, *supra* (1989)].

Currently, HLA typing is routinely done in connection with many medical procedures, e.g., organ transplantation. Rejection of organ grafts is believed to be diminished if the HLA alleles of donor and recipient are identical. The numerous alleles of HLA genes in the population also make HLA typing useful for paternity testing. However, the currently available techniques are incapable of differentiating among all of the polymorphisms associated with the alleles at class I and Class II HLA loci. Other drawbacks to current HLA typing are the availability of standard sera necessary to conduct serological tests, the speed of obtaining test results (i.e., MLC takes 5-7 days), and that only the already known HLA types, but not new polymorphisms, are detected by these techniques. In the case of tissue typing in organ transplants and in relatively high volume genetic evaluations, such as paternity testing, the length of time associated with current HLA typing techniques causes unnecessary delay and the results may not be highly accurate.

Accordingly, there is a need for a method to determine genomic information in highly polymorphic systems, such as the HLA gene complex, that addresses the limitations imposed by previous methods. That is, in the case of the HLA gene complex, a system that is capable of determining the nucleotide sequences of the genes carried by any given individual without the need to have previous knowledge of his or her HLA types as defined by other methods. Furthermore, the invention avoids the use of oligonucleotides specific for each known allele. The technique we present is rapid, requires the use of only a small number of oligonucleotide primers, and can readily detect new

35

polymorphisms by means of their hybridization to DNA on a solid support (oligomer typing) or for sequencing [Triary et al., *supra* (1988); Erlich and Bugawan, *supra*, (1989); Todd et al., *supra* (1987); Saiki et al., *Science*, 230:1350 (1985); Mullis and Faloona, *Methods Enzymol.*, 155:335 (1987); Saiki et al., *Nature*, 324:163 (1986); Scharf et al., *Science*, 233:1076 (1986); Gyllenstein and Erlich, *Proc. Natl. Acad. Sci. USA*, 85:7652 (1988)]. Oligonucleotide typing, although rapid, requires the use of a rather large number of oligonucleotides for each locus and cannot detect previously unidentified sequence polymorphisms, likely to exist in non-Caucasian populations; further, the approach may not be easily applicable to and may not be practical for the analysis of Class I polymorphisms.

Direct sequencing of single-stranded DNA generated by PCR using allele-specific oligonucleotides has been successfully used to examine polymorphism at DQA1 locus [Gyllenstein and Erlich, *supra* (1988)]. Application of this approach to DRB genes is, however, problematic due to the strong sequence homology among DRB1, DRB3, DRB4 and DRB5 genes and the presence of up to four different versions of each of these genes in most individuals (isotypic complexity). The very complex ladders generated by direct sequencing make this present process impractical for accurate and rapid determination of HLA types. Thus, direct sequencing of HLA-PCR products has been limited to previous knowledge of the HLA types

5

sequence variants unidentifiable with more conventional approaches. This system is exemplified by its applicability to the analysis of Class II as well as Class I and Class III genes and is automatable.

#### Summary of the Invention

The present invention relates to a method for determining the nucleic acid sequence of one or more polymorphic genes of a subject by amplifying and direct sequencing genomic or complementary DNA molecules for each allele at each gene locus to be sequenced using conserved and non-conserved (non-allele-specific) oligonucleotide primers. In a broad sense, the method of the present invention involves sequence-based typing (SBT) which provides for unequivocal determination of genetic polymorphism at any genetic locus of interest by direct, simultaneous, sequence analysis of both genomic DNA or expressed (RNA) copies of such a locus. SBT can be employed to determine genetic polymorphism at one or more genetic loci of interest, regardless of the complexity of the polymorphism at these loci, including, for example: (1) simple homozygosity or heterozygosity of a unique locus, as exemplified by DQA or the like; (2) isotypic complexity due to multiple, closely related and closely linked copies of a locus, as exemplified by DRB or the like; and (3) intra-allelic complexity at a locus compounded by interlocus complexity, such as Class I genes or the like. Most known human genetic polymorphisms are of the first, and simplest, type.

Use of the SBT method provides overlapping sequence data comprised of only the copies of the locus of interest as is exemplified by each of the types of HLA loci. The SBT strategy is designed to ensure selection of a given locus with equal representation of each copy of that locus by equal amplification and direct sequencing of mixtures of both alleles of that locus and direct interpretation of the overlapping

6

sequencing patterns generated by this approach. Thus, providing a method for determining genetic polymorphism at one or more genetic loci of interest which can be employed, for example, in HLA typing, detection, evaluation, and/or characterization of genetic diseases such as, for example, sickle cell anemia, cystic fibrosis, Thalassemia, and the like, and detection, evaluation, and/or characterization of polymorphism in genetic loci associated with various cancers such as p53, Ras, myc, associated with carcinomas, leukemias, sarcomas or the like.

Use of the method according to the present invention is exemplified by a system providing for rapid and accurate determination of a major histocompatibility complex class genotype of a subject in a sample (e.g., Class I or Class II). Most particularly, the method is directed to determining at least one HLA Class II gene locus including DRB1, DRB3, DRB4, DRB5, DQB1, DQA1, DPB1 genes. In the case of Class I genotypes, the method is envisioned as being useful to determine A, B, and C loci genes.

To determine a gene locus nucleic acid sequence polymorphism with the method of the present invention, nucleic acid (RNA or DNA) from a sample is isolated. In the case of RNA, cDNA molecules for each allele of at least one gene locus to be sequenced are synthesized by employing a locus-specific oligonucleotide primer that anneals to a conserved region of each allele of each gene locus. According to the present invention, the sample nucleic acid sequence is determined by: amplifying the cDNA molecules or genomic DNA by polymerase chain reaction to generate sufficient product for each allele of each gene locus to be sequenced, with all of the alleles for each gene locus and chromosome to be sequenced being amplified with at least one conserved oligonucleotide primer pair, and at least one of the alleles of each gene locus and chromosome to be

sequencing patterns generated by this approach. Thus,

providing a method for determining genetic polymorphism at one or more genetic loci of interest which can be

employed, for example, in HLA typing, detection, evaluation, and/or characterization of genetic diseases

such as, for example, sickle cell anemia, cystic

fibrosis, Thalassemia, and the like, and detection, evaluation, and/or characterization of polymorphism in genetic loci associated with various cancers such as p53, Ras, myc, associated with carcinomas, leukemias, sarcomas or the like.

Use of the method according to the present

invention is exemplified by a system providing for rapid and accurate determination of a major histocompatibility complex class genotype of a subject in a sample (e.g., Class I or Class II). Most particularly, the method is directed to determining at least one HLA Class II gene locus including DRB1, DRB3, DRB4, DRB5, DQB1, DQA1, DPB1 genes. In the case of Class I genotypes, the method is envisioned as being useful to determine A, B, and C loci genes.

To determine a gene locus nucleic acid sequence polymorphism with the method of the present invention, nucleic acid (RNA or DNA) from a sample is isolated. In the case of RNA, cDNA molecules for each allele of at least one gene locus to be sequenced are synthesized by employing a locus-specific oligonucleotide primer that anneals to a conserved region of each allele of each gene locus. According to the present invention, the sample nucleic acid sequence is determined by: amplifying the cDNA molecules or genomic DNA by polymerase chain reaction to generate sufficient product for each allele of each gene locus to be sequenced, with all of the alleles for each gene locus and chromosome to be sequenced being amplified with at least one conserved oligonucleotide primer pair, and at least one of the alleles of each gene locus and chromosome to be

sequencing patterns generated by this approach. Thus,

providing a method for determining genetic polymorphism at one or more genetic loci of interest which can be

employed, for example, in HLA typing, detection, evaluation, and/or characterization of genetic diseases

such as, for example, sickle cell anemia, cystic

fibrosis, Thalassemia, and the like, and detection, evaluation, and/or characterization of polymorphism in genetic loci associated with various cancers such as p53, Ras, myc, associated with carcinomas, leukemias, sarcomas or the like.

Use of the method according to the present

invention is exemplified by a system providing for rapid and accurate determination of a major histocompatibility complex class genotype of a subject in a sample (e.g., Class I or Class II). Most particularly, the method is directed to determining at least one HLA Class II gene locus including DRB1, DRB3, DRB4, DRB5, DQB1, DQA1, DPB1 genes. In the case of Class I genotypes, the method is envisioned as being useful to determine A, B, and C loci genes.

To determine a gene locus nucleic acid sequence polymorphism with the method of the present invention, nucleic acid (RNA or DNA) from a sample is isolated. In the case of RNA, cDNA molecules for each allele of at least one gene locus to be sequenced are synthesized by employing a locus-specific oligonucleotide primer that anneals to a conserved region of each allele of each gene locus. According to the present invention, the sample nucleic acid sequence is determined by: amplifying the cDNA molecules or genomic DNA by polymerase chain reaction to generate sufficient product for each allele of each gene locus to be sequenced, with all of the alleles for each gene locus and chromosome to be sequenced being amplified with at least one conserved oligonucleotide primer pair, and at least one of the alleles of each gene locus and chromosome to be

1

sequenced being amplified with at least one non-conserved oligonucleotide primer and at least one conserved primer; preparing the products of each PCR for sequencing (clean); sequencing directly the products of each polymerase chain reaction product to detect each allele at each gene locus of each chromosome, with an enzyme appropriate for DNA sequencing, such as Taq polymerase and a conserved primer specific for each locus that is sequenced; and analyzing each sequenced product for each locus and primer combination(s) to determine the genotype of the subject.

In a preferred embodiment of the present invention the sequence of each polymerase chain reaction product for each allele of each gene locus is determined by analyzing each nucleic acid single and/or overlapping ladder generated for each directly sequenced polymerase chain reaction product. The analysis is conducted by comparing the nucleotide sequence of each allele of each gene locus sequence to known sequences for each locus, followed by comparing the sequence of each gene locus amplified with the non-conserved/conserved oligonucleotide primer pair to the nucleotide sequence of each allele of the gene locus amplified with a conserved oligonucleotide primer pair. Comparison of nucleic acid ladders for sequenced alleles can be conducted visually or using computer software.

In a preferred embodiment, the process of the invention is automated for use in rapid genotype determinations, including diagnosis of genetic diseases. Automation of the process includes isolating the sample nucleic acid with an RNA/DNA extractor; amplifying the synthesized cDNA molecule or the isolated DNA molecule by polymerase chain reaction using a thermocycler to generate the polymerase chain reaction products; sequencing the polymerase chain reaction products in an automated sequencing apparatus; and analyzing each sequenced polymerase chain reaction product with the

computer having a database with allelic sequence information and the capacity to conduct the appropriate subtraction algorithm for comparing the Polymerase chain reaction product sequence for each allele amplified with a conserved oligonucleotide primer B to the nucleic acid sequence of each allele sequence with a non-conserved/conserved oligonucleotide primer pair.

The invention further relates to specific groups of oligonucleotide primers useful in the steps of cDNA synthesis, cDNA/genomic DNA amplification by polymerase chain reaction and direct sequencing of the polymerase chain reaction products to determine the nucleotide sequence of each of the alleles at each locus of each chromosome that is amplified. Useful single strand DNA oligonucleotide primers are described in Table 1 herein.

## Brief Description of the Drawings

Figure 1A shows a schematic of the cDNA/PCR sequencing experiments for DRB (DRB1, DRB3, DRB4 and DRB5). DRB1, DRB3 and DRB4 genes are located on chromosome 6, whereas DRB5 is located on chromosome 15.

Figure 1B shows a schematic of the primer binding sites on DRB, DQAI, DPBI, DPAl and DPBl transcripts. Stippled boxes represent primers used in the cDNA synthesis reactions; black boxes represent conserved (or Type 1) primers, used for PCR; checked boxes represent non-conserved (or Type 2) primers, also used for PCR; and blank boxes represent sequencing primers.

Figure 1C shows a schematic of the primer binding sites on DQB1, DRB, DPB1 and DPB1 genes in their exome configuration. Only those primers exclusively

Figure 2A shows a flow-chart of the procedure used for genomic DNA samples are shown in the Figure.

9

named with capital letter in parenthesis; these letters correspond to those shown in Table II (combinations of primers/reaction). Only the "routine" combinations of primers are shown in this Figure.

Figure 2B is a flow-chart of the procedure for forensic samples, where DNA is usually the only available genetic material to work with. DNA in these situations is usually isolated from hair, sperm, blood stains, etc. The combinations of primers per reaction shown in the Figure correspond to the "routine" combinations only.

Figure 3 shows direct sequencing of Class II HLA dsDNA generated using conserved oligonucleotides. Lanes are read from left to right as G-A-T-C. 1, DRB1 ladder for a DRB1\*0201/DRB1\*0302 heterozygote; 2, DQA1 ladder for a DQA1\*0103 homozygous cell line; 3, DRB ladders for a DRB1\*0301, DRB3\*0101/DRB1\*0401, DRB4\*0101 heterozygote. Positions where there is more than one band are indicated on the side of the ladder and the templates they correspond to are indicated at the top of the Figure. To read unambiguously the last 50-60 base pairs of the ladder it is necessary to electrophorese the sequencing gel for an additional hour. Note that the ladders corresponding to the genes at DRB3 or DRB4 loci are fainter in comparison to those corresponding to the genes at DRB1 locus, possibly due to their lower levels of expression. These differences in intensity are generally reproducible and help read the complex overlapping patterns. The positions of the first exon base pair and codon (in parenthesis) that can be read in this Figure are indicated at the bottom of each ladder.

Figure 4 shows direct sequencing of Class II HLA DRB1 dsDNA generated using non-conserved oligonucleotides. Lanes are read from left to right as G-A-T-C. Lane 1, DRB1\*0101/DRB1\*1501, DRB5\*0101 heterozygote cDNA amplified with primer DRB17 (selects DRB5\*0101 cDNA) (left) and DRB16 (selects DRB1\*0101

10

cDNA) (right); Lane 2, DRB1\*1405, DRB4\*0101/DRB1\*0301, DRB3\*0101 heterozygote cDNAs amplified with the 5' primers DRB17 (selects DRB1\*0101 and DRB3\*0101 cDNAs) (left) and DRB16 (selects DRB1\*0405 and DRB3\*0101) (right). Positions where there is more than one band or where the two ladders generated with each primer differ are indicated on the side of the ladders.

#### Detailed Description of the Invention

As used herein, the term "gene" refers to a segment of DNA, composed of a transcribed region and a regulatory sequence that makes possible a transcription. The term "gene locus" refers to the specific place on the chromosome where a gene is located. The term "allele" refers to the multiple forms of a gene that can exist at a single gene locus at a single chromosome and are distinguishable from the other possible alleles by their differing effects on phenotype (detectable outward manifestations of a specific genotype). "Haplotype" refers to the specific allele composition of the genes at multiple loci on the same chromosome. As used herein the term "genotype" refers to the specific allelic composition of a gene at multiple linked loci at each chromosome (2 haplotypes).

The term "oligonucleotide" as used herein refers to a molecule having two or more deoxyribonucleotides or ribonucleotides, preferably more than three deoxyribonucleotides. The exact number of nucleotides in the molecule will depend on the function of the specific oligonucleotide molecule. As used herein the term "primer" refers to a single stranded DNA oligonucleotide sequence, preferably produced synthetically which is capable of acting as a point of initiation for synthesis of a primer extension product which is complementary to a nucleic acid strand to be copied or a point of initiation for sequencing a DNA molecule. In the case of primers intended for use in

35 G-A-T-C. Lane 1, DRB1\*0101/DRB1\*1501, DRB5\*0101

heterozygote cDNA amplified with primer DRB17 (selects DRB5\*0101 cDNA) (left) and DRB16 (selects DRB1\*0101

11 synthesizing cDNA or genomic DNA molecules by polymerase chain reaction products, the length and sequence of the primer must be sufficient to prime the synthesis of extension products in the presence of a polymerization enzyme. Preferably, the length of the primer is from about 5-50 nucleotides, more preferably from about 5-20 nucleotides. Specific length and sequence of the primer will depend on complexity of required DNA or RNA target templates, as well as conditions of primer employment such as temperature, ionic strength, and MgCl<sub>2</sub> concentration.

10 When nested primers are used for sequencing, the number of base pairs separating the amplification and sequencing primers on the DNA template are also important considerations.

15 As used herein, "conserved oligonucleotide primer" (Type 1) refers to an oligonucleotide molecule that corresponds to a region of high DNA sequence conservation (i.e. less than 1-2 nucleotide variations).

20 While the conserved primer need not correspond exactly to the nucleotide template to which it anneals, the conserved primer will have minimal, preferably less than one mismatch with the target nucleotide template.

Functionally, conserved primers are capable of equally priming the target nucleotide (cDNA, PCR product, etc.) at high stringency conditions. In contrast to this, as used herein, "non-conserved oligonucleotide primer" (Type 2) refers to an oligonucleotide molecule that has an intended number of mismatches with the possible target nucleotide sequences. The intended number of mismatches can vary with a preferred number of mismatches being about 1-12. Non-conserved primers are characterized by their selective binding to a limited number of alleles at a given locus or at a group of highly homologous loci. The non-conserved primer will bind to the more complementary allele or group of alleles (two or less than two) (i.e., fewer number of

12 mismatches between primer and target template sequence). The specific combinations of conserved and non-conserved primers and the number of reactions per locus or loci used herein are specifically designed to obtain highly accurate results with minimal expenditure of time and cost.

The present invention is directed to a process for determining the sequences of the alleles of polymorphic gene systems carried by any given individual, such as, for example, the human HLA system, genes related to different human genetic disorders, such as sickle cell anemia, cystic fibrosis, or the like, as well as gene systems associated with various cancers, such as p53, myc, or the like. The present invention is exemplified by its utility for determining polymorphism at HLA loci, particularly Class II and Class I genes, the most polymorphic human genetic loci known today, using enzymatic amplification and direct sequencing of the gene cDNA molecules using a limited number of primers and avoiding the use of allele specific oligonucleotides as much as possible. The present method is particularly well suited to determining allelic sequences of Class II HLA genes, thereby providing complete HLA Class II genotype information for a subject. Using the method of the present invention complete Class II HLA typing (DR, DQ and DP) can be performed in about 16 to 24 hours or less.

Generally, the method of the present invention involves: extraction of sample nucleic acid; in the case of RNA, generation of cDNA; cDNA or genomic DNA amplification; direct sequencing of amplification products; and analysis of the direct sequence information. Generation of cDNA, amplifying the cDNA and direct sequencing the cDNA amplification products is accomplished using oligonucleotide primers with specific characteristics, such as those described herein.

۶۷

#### A. Oligonucleotide Primers

The oligonucleotide primers of the present invention can be synthesized using any known suitable method, such as phosphotriester and phosphodiester methods. Narrang et al., Methods Enzymol., 58:90 (1979). Brown et al., Methods Enzymol., 68:109 (1979).

Oligonucleotides can be prepared using a modified solid support such as a Biosearch 8750 DNA synthesizer. Useful primers can also be isolated from a biological source using appropriate restriction endonucleases which cut double stranded DNA at or near a nucleotide sequence of interest for use as a primer.

### 3. Extraction of Sample Nucleic Acid

In the process of the present invention any source of nucleic acid can be used as the sample nucleic acid, as long as the sample contains the nucleic acid sequence of interest. For example, the sample chosen for the present method can be RNA, DNA or a DNA/RNA hybrid. Typical samples include peripheral blood mononuclear cells, (PBMMC's), lymphoblastoid cell lines (LCL's), hair cells or the like. For determining human HLA Class II and Class I gene polymorphisms LCL's or PBMMC's are preferred. The nucleic acid to be isolated (e.g. RNA or DNA) will depend on the source of genetic material (blood stain, hair, or peripheral blood cells). However, in the case of HLA Class II genes including DRB1-5, DQB1, DQA1, DPB1 the preferred isolated nucleic acid is total cellular RNA when the typing is to be done for transplantation purposes or paternity testing. For forensic uses, genomic DNA may be the preferred genetic material in which case different primer considerations would be used. Cytoplasmic and poly(A) + RNA can also be used. It is envisioned that isolation of sample nucleic acid for the present process can be automated using a DNA/RNA extractor (such as

Model 341 DNA extractor available from Applied Biosystems, Inc.; Foster City, CA).

5      C. Generation of cDNA

5      Complementary DNA (cDNA) of the sample nucleic acid is generated using specific oligonucleotide primers and cloned reverse transcriptase following general conditions suggested by the enzyme manufacturer (Bethesda Research Laboratories, Gaithersburg, MD).

10     Specific differences in type and amount of primers used, dNTP concentrations and elongation times will be readily apparent to those of skill in the art based on the Examples that follow.

### C. Generation of cDNA

5 Complementary DNA (cDNA) of the sample nucleic acid is generated using specific oligonucleotide primers and cloned reverse transcriptase following general conditions suggested by the enzyme manufacturer (Bethesda Research Laboratories, Gaithersburg, MD).

10 Specific differences in type and amount of primers used, dNTP concentrations and elongation times will be readily apparent to those of skill in the art based on the Examples that follow.

THE JOURNAL OF CLIMATE

## 15 D. Polymerase Chain Reaction

Amplification of cDNA or genomic DNA for each gene locus of interest is accomplished using the polymerase chain reaction (PCR) as generally described in U.S. Pat. Nos. 4,683,195 and 4,683,202 to Mullis. The PCR consists of many repetitions of a cycle which consists of: (a) a denaturation step, which melts both strands of a DNA molecule; (b) an annealing step, which is aimed at allowing the primers to anneal specifically to the melted strands of the DNA molecule; and (c) an extension step, which incorporates to the primers deoxyribonucleotides complementary to those of the strand of DNA to which the primers are annealed. The PCR process, as indicated in the Examples, can be conducted using a Thermocycler (Perkin-Elmer, Cetus, Emeryville, CA).

The present invention introduces the use of non-conserved oligonucleotides in the PCR procedure specifically designed to solve the problems associated with, for example, detecting, evaluating, and/or characterizing polymorphism at a polymorphic gene locus or loci of an individual. In the case of HLA typing the use of non-conserved oligonucleotides addresses the

non-conserved oligonucleotides in the PCR procedure specifically designed to solve the problems associated with, for example, detecting, evaluating, and/or characterizing polymorphism at a polymorphic gene locus or loci of an individual. In the case of HLA typing, the use of non-conserved oligonucleotides addresses the

15

problems one would face in performing HLA typing by sequencing DNA amplified exclusively by using conserved oligonucleotides or allele specific oligonucleotides (see below).

It is understood that the PCR process is designed for the amplification of specific genes with the use of oligonucleotides specific for the particular gene to be amplified. However, even using completely matched primers, in most cases the PCR is not absolutely specific. In the case of HLA typing, for HLA-DRB genes and Class I genes, the use of conserved primers in PCR will generate complex mixtures of templates, which upon direct sequencing will be seen as overlapping sequencing ladders, cumbersome to interpret. Therefore, genes for

which the exact nucleotide sequence information is unknown can not be achieved with an adequate level of certainty. Use of non-conserved oligonucleotides which can selectively anneal under high stringency conditions to two or fewer alleles of a gene locus or group of homologous loci can provide sequence information for the different genes at highly homologous loci in complex heterozygote combinations. Thus, the present invention provides a method useful for determining the genotype for polymorphic gene loci. This is of particular importance to HLA typing, and is applicable to Class I HLA typing as well as Class II typing.

The difference between non-conserved primers and allele-specific oligonucleotides resides in that the latter can only be used when the presence of a particular allele is known, and also requires the use of a specific primer for each of the alleles of the polymorphic system. Thus, combining use of a non-conserved primer and conserved primers to amplify the separate alleles of highly homologous polymorphic gene loci can provide simpler DNA polymerase chain reaction product combinations sufficient to allow unambiguous interpretation of direct sequencing ladders of each

16

allele for genotype determinations with moderate expenditure of time and economical cost.

The conditions used for the PCR reactions are preferably the same except for the temperature used in the annealing step, which is different depending on the type of primer used, conserved (Type 1) or non-conserved (Type 2). Reactions that use the former primer type are preferably performed at 37°C in the annealing step of the cycle, whereas this step is preferably performed at about 55°C to 60°C in reactions that use the later type of primers. The concentrations of primers, and buffers used will be apparent from and include the process parameters described in the Examples that follow.

#### **E. Direct Sequencing Of PCR Products**

Direct sequencing of double-stranded DNA generated by the PCR is accomplished using an enzyme appropriate to DNA sequencing, such as Taq Polymerase, or the like, and specific combinations of reagents at appropriate concentrations. The sequencing procedure can be conducted in an automatic sequencing apparatus such as the 373A Model DNA Sequencer from Applied Biosystems Inc. (Foster City, CA). The reagents, including sequencing primers and nucleic acid termination mixtures will be understood by those of skill in the art based on the direct sequencing procedure specified in the following Examples.

#### **F. Analysis Of Direct Sequenced PCR Products**

The nucleic acid ladders resulting from direct sequencing the cDNA or genomic DNA for each gene locus of interest can be assessed visually from autoradiograms or by employing a computer programmed with nucleotides sequence information for all alleles of all haplotypes and procedures for comparing sequenced alleles and known alleles of gene loci of interest. In a preferred embodiment of the present invention, the evaluation of

15

allele for genotype determinations with moderate expenditure of time and economical cost.

The conditions used for the PCR reactions are preferably the same except for the temperature used in the annealing step, which is different depending on the type of primer used, conserved (Type 1) or non-conserved (Type 2). Reactions that use the former primer type are preferably performed at 37°C in the annealing step of the cycle, whereas this step is preferably performed at about 55°C to 60°C in reactions that use the later type of primers. The concentrations of primers, and buffers used will be apparent from and include the process parameters described in the Examples that follow.

#### **E. Direct Sequencing Of PCR Products**

Direct sequencing of double-stranded DNA generated by the PCR is accomplished using an enzyme appropriate to DNA sequencing, such as Taq Polymerase, or the like, and specific combinations of reagents at appropriate concentrations. The sequencing procedure can be conducted in an automatic sequencing apparatus such as the 373A Model DNA Sequencer from Applied Biosystems Inc. (Foster City, CA). The reagents, including sequencing primers and nucleic acid termination mixtures will be understood by those of skill in the art based on the direct sequencing procedure specified in the following Examples.

#### **F. Analysis Of Direct Sequenced PCR Products**

The nucleic acid ladders resulting from direct sequencing the cDNA or genomic DNA for each gene locus of interest can be assessed visually from autoradiograms or by employing a computer programmed with nucleotides sequence information for all alleles of all haplotypes and procedures for comparing sequenced alleles and known alleles of gene loci of interest. In a preferred embodiment of the present invention, the evaluation of

15

allele for genotype determinations with moderate expenditure of time and economical cost.

The conditions used for the PCR reactions are preferably the same except for the temperature used in the annealing step, which is different depending on the type of primer used, conserved (Type 1) or non-conserved (Type 2). Reactions that use the former primer type are preferably performed at 37°C in the annealing step of the cycle, whereas this step is preferably performed at about 55°C to 60°C in reactions that use the later type of primers. The concentrations of primers, and buffers used will be apparent from and include the process parameters described in the Examples that follow.

#### **E. Direct Sequencing Of PCR Products**

Direct sequencing of double-stranded DNA generated by the PCR is accomplished using an enzyme appropriate to DNA sequencing, such as Taq Polymerase, or the like, and specific combinations of reagents at appropriate concentrations. The sequencing procedure can be conducted in an automatic sequencing apparatus such as the 373A Model DNA Sequencer from Applied Biosystems Inc. (Foster City, CA). The reagents, including sequencing primers and nucleic acid termination mixtures will be understood by those of skill in the art based on the direct sequencing procedure specified in the following Examples.

#### **F. Analysis Of Direct Sequenced PCR Products**

The nucleic acid ladders resulting from direct sequencing the cDNA or genomic DNA for each gene locus of interest can be assessed visually from autoradiograms or by employing a computer programmed with nucleotides sequence information for all alleles of all haplotypes and procedures for comparing sequenced alleles and known alleles of gene loci of interest. In a preferred embodiment of the present invention, the evaluation of

15

allele for genotype determinations with moderate expenditure of time and economical cost.

The conditions used for the PCR reactions are preferably the same except for the temperature used in the annealing step, which is different depending on the type of primer used, conserved (Type 1) or non-conserved (Type 2). Reactions that use the former primer type are preferably performed at 37°C in the annealing step of the cycle, whereas this step is preferably performed at about 55°C to 60°C in reactions that use the later type of primers. The concentrations of primers, and buffers used will be apparent from and include the process parameters described in the Examples that follow.

#### **E. Direct Sequencing Of PCR Products**

Direct sequencing of double-stranded DNA generated by the PCR is accomplished using an enzyme appropriate to DNA sequencing, such as Taq Polymerase, or the like, and specific combinations of reagents at appropriate concentrations. The sequencing procedure can be conducted in an automatic sequencing apparatus such as the 373A Model DNA Sequencer from Applied Biosystems Inc. (Foster City, CA). The reagents, including sequencing primers and nucleic acid termination mixtures will be understood by those of skill in the art based on the direct sequencing procedure specified in the following Examples.

#### **F. Analysis Of Direct Sequenced PCR Products**

The nucleic acid ladders resulting from direct sequencing the cDNA or genomic DNA for each gene locus of interest can be assessed visually from autoradiograms or by employing a computer programmed with nucleotides sequence information for all alleles of all haplotypes and procedures for comparing sequenced alleles and known alleles of gene loci of interest. In a preferred embodiment of the present invention, the evaluation of

17

gene locus alleles involves a two step process: (a) comparison of the gene sequences of each polymerase chain reaction product (i.e., conserved and non-conserved primer products) with a library of known genotype information such as the information obtained on homologous cell lines very well characterized by methods other than sequencing [Marsh and Bodmer, Immunogenetics, 31:131 (1990)] as well as sequences of individual alleles; followed by (b) comparison of direct sequence information for the polymerase chain reaction product of an allele of a gene locus amplified with a conserved oligonucleotide primer pair and polymerase chain reaction product of alleles of a gene locus or loci amplified with a conserved/non-conserved Primer Pair.

This comparison employs a substitution algorithm or visual cancellation of duplicative sequence ladder information to generate the specific sequence information for each allele of a gene locus.

It is envisioned that the process of the present invention can be used to amplify and sequence known and unknown highly polymorphic systems (e.g., genetic disease-related genes, cancer-related genes, and HLA typing, including Class I, Class II, and Class III HLA typing, and the like). The present process is believed to be useful for paternity testing and forensic medicine, with more accuracy than restriction fragment length polymorphism (RFLP), DNA fingerprinting or dot blot-detection systems. While in the latter only a hybridization pattern is observed, direct sequencing of amplified products shows the exact nucleotide sequence of the amplified genes, and hence is more accurate and reliable.

The method is particularly well suited for Class II HLA typing, reducing its costs, increasing its speed and especially improving its accuracy. As evidenced by the following Examples, sequence polymorphism analysis of DRB1, DRB3, DRB4, DRB5, DQB1,

18

DQA1, DPB1 and DPB1 genes can be rapidly performed in any subject of unknown HLA type by means of enzymatic amplification and direct sequencing of Class II genes using a limited number of conserved and non-conserved oligonucleotides. The approach described herein is entirely automatable using currently available technology and, as opposed to previously described methods using oligonucleotide probes and dot blots, has the advantage of detecting the presence of new allelic sequences or sequence microheterogeneity at the population level. The methodology of present invention is envisioned to be useful for detailed analyses of the effects of sequence allelism at different Class II HLA loci on graft survival after allogeneic transplantation. The method of the present invention allows rapid and precise sequence analysis of Class II HLA polymorphism in studies of human disease and may be of interest in the search for new Class II sequence variants in large populations of subjects.

The present invention is further described by illustration in the following Examples which are not intended to limit the invention.

**EXAMPLE I****1. Preparation of Oligodeoxyribonucleotide Primers and Sequence Primer Combinations Useful for cDNA/PCR/Sequencing Reactions of Class II HLA Genes**

All of the oligodeoxyribonucleotide primers described herewithin were synthesized as described below:

Automated Synthesis of oligodeoxyribonucleotide primers: The b-cyanoethylphosphoamidites, obtained from Milligen-Bioscience (Novato, CA), were sequentially condensed to a nucleoside derivatized controlled pore glass support using a Bioscience 8750 DNA synthesizer. Condensation cycles included detritylation with dichloroacetic acid in dichloromethane, followed by condensation with benzotriazole and capping with acetic

&lt;/div

19  
 anhydride and 1-methylimidazole in tetrahydrofuran and pyridine, with each cycle time being approximately 9 minutes. Yields at each step were >99% as determined measuring dimethoxytrityle alcohol release. The methodology for oligodeoxynucleotide synthesis is described in Carrthers, et al., Methods Enzymol., 154:287 (1987).

Deprotection and purification of  
oligodeoxyribonucleotide primers: Deprotection and  
purification of oligodeoxyribonucleotide primers was  
performed using the procedure described by Schulhof et  
al., *Nucl. Acids Res.*, 15:397 (1987). Briefly, the  
oligodeoxyribonucleotide was removed from the solid  
support by exposure to concentrated ammonium hydroxide  
at room temperature for about one hour. The solution  
containing the partially deprotected  
oligodeoxyribonucleotide was brought to 65°C for 16  
hours. Ammonia was removed and the residue was  
subjected to chromatography on a C18 reverse-phase  
column (RP 304, BioRad, Richmond, VA) using a linear  
gradient of 14 to 20% acetonitrile in 0.1 molar  
ammonium triethylamine, pH 7.0. The dimethoxytrityle

oligodeoxyribonucleotide by treatment with 70% acetic acid. The detritylated oligodeoxyribonucleotide was recovered by precipitation in ether, vacuum centrifuged until dry, resuspended in water and quantitated by measuring its absorbance at 260-

Using the above procedure, the following oligonucleotide primers corresponding to specified regions of HLA Class II DQA, DQB, DRB, DPB and DPA loci were synthesized (see Table I below) and extensively tested:

No.	Sequence	Clustering (Seqs.)	Type	Step
1	DBPB7	5'-GGTCCTGAGGCCCTCGTC-3'	RT/PCR	Anneal
2	DBPB20	5'-GTGCCTGAGGCCCTCGTC-3'	RT/PCR	DBPB1
3	DBPA9	5'-GCTGAGCTTACGAGCTTGAG-3'	RT/PCR	DBPB1
4	DBPB13	5'-AGAGACTCCCGAGGAACTTC-3'	RT/PCR	DBPB1
5	DBPB22	5'-AGAGACTCCCGAGGAACTTC-3'	RT/PCR	DBPB1
6	DBPA10	5'-CTGCCTCCATGAGCTGTC-3'	RT/PCR	DBPB1
7	DBPB32	5'-CTGCCTCCATGAGCTGTC-3'	RT/PCR	DBPB1
8	DBPB922	5'-CTGCCTCCATGAGCTGTC-3'	RT/PCR	DBPB1
9	DBPB31	5'-TTAAGGAAATCTGTCATCTGG-3'	RT/PCR	DBPB1
10	DBPB30	5'-ATGGGAAATCTGTCATCTGG-3'	RT/PCR	DBPB1
11	DBPB5	5'-GCGATACGAGCTGTCACAC-3'	RT/PCR	DBPB1
12	DBPA12	5'-GCTCGCTGACATGTCCTGG-3'	RT/PCR	DBPB1
13	DBPA29	5'-CAGCCTGCAGCTGACATGTCCTGG-3'	RT/PCR	DBPB1
14	DBPA30	5'-TAACCTGCAGCTGACATGTCCTGG-3'	RT/PCR	DBPB1
15	DBPA29	5'-CAGCCTGCAGCTGACATGTCCTGG-3'	RT/PCR	DBPB1
16	DBPB440	5'-GCCTCTGCAGACAGCTGACCTGG-3'	RT/PCR	DBPB1
17	DBPB1401	5'-GAGCTGATGAACTTATCTTCAG-3'	RT/PCR	DBPB1
18	DBPB1402	5'-ATAATGGCTGATGAACTTATCTTCAG-3'	RT/PCR	DBPB1
19	DBPB1403	5'-GCGCTGATGAACTTATCTTCAG-3'	RT/PCR	DBPB1
20	DBPB1406	5'-GCCTCTGCAGACAGCTGACCTGG-3'	RT/PCR	DBPB1
21	DRBB825	5'-AACCCGATAGCTGCTGCA-3'	RT/PCR	DBPB1
22	DRBB824	5'-GGGGAAACGCCAGACAGCTTC-3'	RT/PCR	DBPB1
23	DRBB10	5'-GGGGAAACGCCAGACAGCTTC-3'	RT/PCR	DBPB1
24	DRBB11	5'-GTGTGTCCTGCAGAGGCC-3'	RT/PCR	DBPB1

oligonucleotides used for the cDNA/PCR/Sequencing Reactions

No.	Sequencing (Seqd.)	Type 1	Template	Step	StepR/T	DPR12	5'-CTTGGAGGGAACACATTAC-3'	97-103	DPR1	DPR1	RNA	Seq/R/T			
25	DPR13	5'-ACGTGATGGTCCTGCAT-3'	-12/-5	bp-pA-2/-62	DPR1	DNA	Seq	27	DPR14	5'-AGAGGAGAAAGAGGATTAAGA-3'	-10/-110	DPR1	DNA	Seq	
26	DPR15	5'-GCGCCCAAAGGCCCTCATCA-3'	inttron 3	bp 39/59	DPR1	DNA	PCR	28	DPR15	5'-GCCCTGGCGAACGGGCCGGGG-3'	inttron 2	bp-pA-2/-62	DPR1	DNA	PCR
27	DPR16	5'-CGGCCCAAAGGCCCTCATCA-3'	inttron 3	bp 39/59	DPR1	DNA	PCR	29	DPR17	5'-CGCTCAGGAAAGGCCCTCATCA-3'	inttron 3	bp 6/-26	DPR1	DNA	Seq
28	DPR17	5'-CGCTCAGGAAAGGCCCTCATCA-3'	inttron 3	bp 6/-26	DPR1	DNA	Seq	30	DPR17	5'-CGCTCAGGAAAGGCCCTCATCA-3'	inttron 2	bp 6/-26	DPR1	DNA	Seq
29	DPR18	5'-CGGCCCAAAGGCCCTCATCA-3'	inttron 2	bp 6/-26	DPR1	DNA	PCR	31	DPR14	5'-GCTCACATGGCGGAGGATGG-3'	104-110	DPR1	DNA	RNA	R/T/PCR
30	DPR15	5'-GATATCGAGAAGCTGATATTC-3'	-17/-23	DPR1	DNA	RNA	PCR	32	DPR15	5'-GATATCGAGAAGCTGATATTC-3'	-17/-23	DPR1	DNA	RNA	PCR
31	DPR14	5'-GCTCACATGGCGGAGGATGG-3'	104-110	DPR1	DNA	RNA	R/T/PCR	33	DPR15	5'-GATATCGAGAAGCTGATATTC-3'	-17/-23	DPR1	DNA	RNA	PCR
32	DPR15	5'-GATATCGAGAAGCTGATATTC-3'	-17/-23	DPR1	DNA	RNA	PCR	34	DPR17	5'-GTCCTGGGAAAGCTGGGACACTC-3'	-3/-9	DPR1	DNA	RNA	Seq
33	DPR15	5'-GATATCGAGAAGCTGATATTC-3'	-17/-23	DPR1	DNA	RNA	PCR	35	DPR10	5'-CTCTAGACCTTGAGACACATTCG-3'	-50	DPR1	DNA	RNA	Seq
34	DPR17	5'-GTCCTGGGAAAGCTGGGACACTC-3'	-3/-9	DPR1	DNA	RNA	Seq	36	DPR11	5'-AGTCGAGGCTGGCAGAGAGG-3'	bp 55-71	DPR1	DNA	DNA	PCR
35	DPR10	5'-CTCTAGACCTTGAGACACATTCG-3'	-50	DPR1	DNA	DNA	PCR	37	DPR12	5'-GCCCTGGCGGCTGGACG-3'	76-82	DPR1	DNA	DNA	Seq
36	DPR11	5'-AGTCGAGGCTGGCAGAGAGG-3'	bp 55-71	DPR1	DNA	DNA	PCR	38	DPR19	5'-CTGCCCTGGCATCTGCATATTC-3'	59-65	DPR1	DNA	DNA	PCR
37	DPR12	5'-GCCCTGGCGGCTGGACG-3'	76-82	DPR1	DNA	DNA	Seq	39	DPR20	5'-GCCACAGGCGGAGACGATTTA-3'	222-228	DPR1	DNA	RNA	RT
38	DPR19	5'-CTGCCCTGGCATCTGCATATTC-3'	59-65	DPR1	DNA	DNA	PCR	39	DPR20	5'-GCCACAGGCGGAGACGATTTA-3'	214-220	DPR1	DNA	DNA	Seq
39	DPR20	5'-GCCACAGGCGGAGACGATTTA-3'	222-228	DPR1	DNA	DNA	Seq	40	DPR21	5'-ACCTGGAAATACCTGCATAC-3'	68-74	DPR1	DNA	DNA	Seq
41	DPR21	5'-ACCTGGAAATACCTGCATAC-3'	68-74	DPR1	DNA	DNA	Seq								

No.	Type 2 Specification (say.)	Type 1 Specification (say.)	Template	Annex I	Locus (if)	Annex II	Step
-----	--------------------------------	--------------------------------	----------	---------	------------	----------	------

All the above type I proteins are annealed at 37°C and the type II proteins are annealed at 55°C. When the latter are annealed at 37°C in the PCR, they do not dissociate during annealing when heating by steps of 1°C per cycle, while the type II proteins dissociate during annealing when heating by steps of 1°C per cycle. The difference between the two types of proteins is that the type II proteins have a higher melting temperature than the type I proteins.

23  
2. Combinations of Primers for cDNA/PCR/Sequence ReactionsReactions

There are specific combinations of oligonucleotide primers for each reaction and for each 5 locus, including cDNA synthesis, PCR amplification and direct sequencing, which are designed to provide all the necessary sequence information for obtaining highly accurate, fast and inexpensive typing results. These combinations are listed in Table II below as "routine" 10 combinations. In addition, Table II includes a list of "alternative" combinations of oligonucleotides for each locus which may be used to confirm results obtained with the "routine" combinations for a particular locus not expected according to, for instance, known haplotypic 15 maps. These "unexpected" results are usually indicative of the existence of new alleles and/or haplotypes, which can be confirmed with the use of the alternative combinations of oligonucleotides. In any case, each of these combinations of oligonucleotides is characterized by its ability to generate an end-product (sequencing ladder) which is suitable of being accurately read by the naked eye or processed by computer operated under appropriate software.

For typing purposes in the clinical setting, such as in transplantation, the method uses RNA isolated from peripheral blood mononuclear cells as starting material; for forensic purposes, however, DNA is often the only available template. Although for each template (RNA or DNA) different combinations of oligonucleotides are used (see Table II), the general strategy for 20 typing, including the interpretation of the results is essentially the same. The specific combinations of primers for "routine" RNA and DNA analysis, respectively, are described below in more detail. The 25 general overview of the HLA typing strategy is shown in Figures 1 and 2 and discussed further in Examples 2 and 3.

TABLE II  
Combinations of Primers for cDNA/PCR/Seq Reactions

## 1. RNA

Routine	Type	cDNA	PCR	A.T.	Seq*
A. 1	DRB20	DRB11	37°C		DRB30/DRB12
B. 2	DRB20	DRB23	55°C		DRB30/DRB12
C. 2	DRB20	DRB24	55°C		DRB30/DRB12
D. 2	DRB20	DRB25	55°C		DRB30/DRB5
E. 1	DQB7	DQB13	37°C		DQA30/DQA29***
F. 1	DQA9	DQA10	37°C		DPA10/DPB13
G. 1	DPB11	DPB10	37°C		DPB12/DPB13
H. 1	DPA14	DPA15	37°C		DPA16/DPB17
I. 1	DPA19	DPA18	37°C		DPA20/DPA21****
<b>Alternative</b>					
J. 2	DRB20	DRB16	55°C		DRB30/DRB12
K. 2	DRB20	DRB17	55°C		DRB30/DRB12
L. 1	DRB20	DRB22	37°C		DRB30/DRB12
M. 1	DQB7	DQB6	37°C		DQB13
N. 2	DQB7	DQB6	55°C		DRB30/DRB5
O. 2	DQB7	DQB14	55°C		DQB30/DQB5
P. 2	DQB7	DQB15	55°C		DQB30/DQB5
Q. 1	DPB12	DPB10	37°C		DPB13
R. 1	DPA16	DPA15	37°C		DPA17

## 2. DNA

Routine	Type	PCR1	PCR2	A.T.	Seq
S. 1	DRB1406	DRB22	37°C		
DRB12/DRB1406****					
T. 2	DRB1406	DRB24	55°C		DRB12/DRB1400
U. 2	DRB1406	DRB25	55°C		DRB12/DRB1400
V. 2	DRB1406	DRB23	55°C		DRB12/DRB1400
W. 1	DQB932	DQB931	37°C		DQB5
X. 1	DPB14	DPB15	37°C		DPB16/DPB17
Y. 1	DPB10	DPB11	37°C		

Routine	Type	PCR1	PCR2	A.T.	Seq
Z. 1	DRB12	DRB824	37°C		DRB825
AA. 2	DRB1401	DRB1402	55°C		DRB1403#
AB. 2	DRB1406	DRB16	55°C		DRB825/DRB12
AC. 2	DRB1406	DRB17	55°C		DRB825/DRB12
AD. 1	DPB14	DPB16	37°C		DPB17

(\*) For sequencing DRB and DQB two alternative sequencing primers are indicated, both sequencing the positive strand of DNA.

25

(\*\*) Primer DRB22 is used to sequence the negative strand whenever new allelic sequences are identified.

(\*\*\*) Each DQ<sub>1</sub> sequencing primer anneals to a different strand. Reaction L uses an alternative amplification primer (DRB 22 instead of DRB11) in hypothetical situations where homozygosity may not be expected according to the rest of the haplotype. Reaction M is used for sequencing the negative strand of DQB1 in situations where new allelic sequences are identified.

(\*\*\*\*) Sequencing of the third exon is necessary to distinguish among certain DP<sub>A1</sub> alleles.

(\*\*\*\*\*) Primer DRB1400 may be used in sequencing amplified DRB genes from genomic DNA to read the sequences immediately following the 3' amplification primer. Reaction Q, R, Z and AD are alternative combinations for confirming homozygosity at the corresponding loci which may not be expected according to the rest of the Class II haplotype.

(#) This primer combination is used to distinguish between DRB1\*0701 and DRB1\*0702, which differ by a single base pair in their third exons.

26

EXAMPLE II  
Protocol: HLA Class II "Typing" by Direct Sequencing  
of DRB, DQB, DPA and DPB Genes

1. Cell Lines and Subjects

5 Lymphoblastoid cell lines (LCLs) representing each of the known Class II haplotypes defined at the 10th International Histocompatibility Workshop [Dupont, Hum. Immunol., 26, 3 (1989)] were provided by Dr. Miriam Segall (University of Minnesota). Forty unrelated subjects who had been previously serologically typed for Class I and Class II antigens were also studied. The serological types of each of the subjects under study were not known to the investigator performing the sequence analysis at the time the analysis was performed. These subjects included both healthy and affected (insulin-dependent diabetes and autoimmune thyroid disease) individuals. The sequenced haplotypes, many in heterozygote combinations, included: DR7 (n=3), DRW17 (n=26), DR4 (n=16), DRW11 (n=8), DRw8 (n=4), DR1 20 (n=6), DRW15 (n=6), DRW16 (n=2), DRW13 (n=2), DRW14 (n=2), DR212 (n=3), DR5x6 (n=3). The cell lines and heterozygote combinations tested are shown in Table III. Since the complexity at DPA and DPB loci is similar to that of DQ genes, the primer combinations for DPA and 25 DPB typing were optimized in a smaller group of homozygote and heterozygote subjects.

2. HLA-DRB, DQB and DPA Transcript Amplification Using Conserved and Non-Conserved Oligonucleotides

30 Total cellular RNA was prepared from (1 µg) from 5-10x10<sup>6</sup> peripheral blood mononuclear cells (PBMC) or lymphoblastoid cell lines (LCLs) by cesium chloride centrifugation [Chirgwin et al. Biochemistry, 18, 5249 (1979)]. Alternatively, total RNA from peripheral blood (2-10 ml) was partially purified using a much faster protocol [Gough, Anal. Biochem., 173, 93 (1988)]. One microgram of total cellular RNA was reverse transcribed with Moloney leukemia virus reverse transcriptase

27

(MLVRT) (200 u, Bethesda Research Laboratories) in 50 mM Tris HCl, pH 8.3, 75 mM KCl, 10 mM DTT, 3mM MgCl<sub>2</sub>, in the presence of the ribonuclease inhibitor RNAs in (10 units, Promega), 75 uM each dNTP and 10 pmols of a specific non-sense primer (Table II) in a 20 ml final volume for 30-45 min at 37°C. Eight  $\mu$ l of 10X PCR buffer (500 mM KCl, 100 mM Tris-Cl, pH 8.3, 7.5-15 mM MgCl<sub>2</sub>, 0.1% gelatin) were added after the incubation period. A 5'-primer (20 pmols) (Type 1 or Type 2 primers, respectively, see Table II) plus 10 pmols of the non-sense primer and two units of Taq polymerase were also added and the final volume was adjusted to 100  $\mu$ l with distilled water. The reaction mixture was subjected to 35 cycles of 30 sec at 94°C, 30 sec at 37°C or 55°C and 30 sec at 72°C using a Perkin-Elmer Cetus Thermocycler [see Saiki et al., *supra* (1985); Mullis and Falona, *supra* (1987); Saiki et al., *supra* (1986); Scharf et al., *supra* (1986)]. The primers used here, their corresponding sequences and the regions to which they anneal are shown in Table II. The reactions for each locus are usually performed in separate microfuge tubes. However, when using conserved primers, the cDNA and PCR reactions for all loci (DRB, DQA, DQB, DPA and DPB) can be successfully performed simultaneously in the same tube.

28

routinely sequenced for typing; sequencing of the other strand is performed in cases where a new allelic sequence is suspected. Eighty to 100 ng of primer were end-labelled with 10 pmol of gamma-P32 labelled ATP (5000 Ci/mmol, 10  $\mu$ Ci/ $\mu$ L) and 5 units of T4 polynucleotide kinase (Promega Biotec) in a 10  $\mu$ l final volume. Ten ng of primer (1  $\mu$ l) were added to the sequencing mixture without extraction of unincorporated labelled ATP, boiled for 5 min., and then left at room temperature for 15 min. Eight units of recombinant Taq polymerase (USB) were added to the mixture. Four  $\mu$ l of the annealed primer/template mixture were later added to 4  $\mu$ l of each of the stop nucleotide mixes: a) Term mix ddG: 15 microm each dGTP, dATP, dCTP, dTTP; 45 microm ddGTP; b) Term mix ddA: 15 microm each dGTP, dATP, dCTP, dTTP; 600 microm ddATP; c) Term mix ddT: 15 microm each dGTP, dATP, dCTP, dTTP; 1200 microm ddCTP; d) Term mix ddC: 15 microm each dGTP, dATP, dCTP, dTTP; 450 microm ddCTP. The reactions were allowed to proceed for 20 two consecutive periods of 10 min. at 72-74°C. After the second cycle, each reaction was chased with 2  $\mu$ l of a 7.5  $\mu$ M mixture of ATP, GTP, TTP, CTP, and allowed to proceed for 5 min. After spinning down, the reaction was stopped by adding 4 ml of 95% (vol/vol) formamide/20 mM EDTA, heated to 80°C for 5 min. and loaded on a .4 mm thick 6% polyacrylamide/7M urea gel. Electrophoresis was performed at 2500 V for 2 hr, the gel fixed in 5% (vol/vol) glacial acetic acid/5% (v/v) methanol for 15 min, dried, and exposed to Kodak X-Omat film for 4 to 12 hours.

### 3. Direct Sequencing of Amplified Products with Tag Polymerase

The reaction mixture (100  $\mu$ l) was freed of unincorporated dNTPs and excess of oligonucleotides by spin-dialysis using Centricon-100 (Amicon) or Ultrafree-100 (millipore) microconcentrators. One half of the retentate (20  $\mu$ l) was dried down and resuspended in 15  $\mu$ l of 1X Tag sequencing buffer (50 mM Tris-HCl, pH 9, 10 mM MgCl<sub>2</sub>). Internal oligonucleotides were used for priming the sequencing of DQB, DRB, DQA, DPB and DPA genes, respectively (Table II). Primers for sequencing each strand are listed in Table III. Only one strand is

29

routinely sequenced for typing; sequencing of the other strand is performed in cases where a new allelic sequence is suspected. Eighty to 100 ng of primer were end-labelled with 10 pmol of gamma-P32 labelled ATP (5000 Ci/mmol, 10  $\mu$ Ci/ $\mu$ L) and 5 units of T4 polynucleotide kinase (Promega Biotec) in a 10  $\mu$ l final volume. Ten ng of primer (1  $\mu$ l) were added to the sequencing mixture without extraction of unincorporated labelled ATP, boiled for 5 min., and then left at room temperature for 15 min. Eight units of recombinant Taq polymerase (USB) were added to the mixture. Four  $\mu$ l of the annealed primer/template mixture were later added to 4  $\mu$ l of each of the stop nucleotide mixes: a) Term mix ddG: 15 microm each dGTP, dATP, dCTP, dTTP; 45 microm ddGTP; b) Term mix ddA: 15 microm each dGTP, dATP, dCTP, dTTP; 600 microm ddATP; c) Term mix ddT: 15 microm each dGTP, dATP, dCTP, dTTP; 1200 microm ddCTP; d) Term mix ddC: 15 microm each dGTP, dATP, dCTP, dTTP; 450 microm ddCTP. The reactions were allowed to proceed for 20 two consecutive periods of 10 min. at 72-74°C. After the second cycle, each reaction was chased with 2  $\mu$ l of a 7.5  $\mu$ M mixture of ATP, GTP, TTP, CTP, and allowed to proceed for 5 min. After spinning down, the reaction was stopped by adding 4 ml of 95% (vol/vol) formamide/20 mM EDTA, heated to 80°C for 5 min. and loaded on a .4 mm thick 6% polyacrylamide/7M urea gel. Electrophoresis was performed at 2500 V for 2 hr, the gel fixed in 5% (vol/vol) glacial acetic acid/5% (v/v) methanol for 15 min, dried, and exposed to Kodak X-Omat film for 4 to 12 hours.

### RESULTS

#### 1. Sequence-Based Typing of DR and DQ Polymorphic Genes in Homozygous Typing Cells

Homozygous lymphoblastoid cell lines (LCLs) from the panel of the 10th International Histocompatibility Workshop (Table III) were used as an initial test of the methodology. In total, these cell

35

29

Lines were representative of most of the known DR and DQ alleles at the time the analysis was conducted.

Total cellular RNA isolated from homozygous ICLs was reverse-transcribed and the resultant cDNAs amplified using conserved oligonucleotides specific for DRB1/DRB3/DRB4/DRB5 or DQA1 genes as described in the preceding protocol. The conserved or Type 1 oligonucleotide primers anneal to regions of conserved DNA sequences; these regions are identical among the known alleles at each locus and flank the second exon of Class II genes. These conserved primers, as opposed to non-conserved or Type 2 primers, are designed to amplify all known alleles at DRB, DQA1 and DQB1 loci and, thus, all possible combinations of these alleles in any given heterozygote. The Type 1 oligonucleotides did not cross-amplify templates at loci other than those specified by the oligonucleotides (i.e., the DQA1 primers did not amplify DRB or DQB1 transcripts and vice versa); as expected, the DRB primers also amplified any DRB3, DRB4 or DRB5 transcripts present in addition to DRB1. Sequencing of these amplified templates was performed using a Type 1 primer annealing to a conserved region of the cDNAs internal to the sequence recognized by the amplification primers. Figure 1A shows the general strategy for the method (SBT) and Figure 1B shows the relative position of each of the oligonucleotides used for the cDNA, PCR and sequencing reactions on the mature DRB, DQA and DQB mRNA molecules. The sequences of these primers, the loci they are specific for, the specific positions (codons) to which they anneal and the reaction(s) they are used in are indicated in Table II where the specific combinations of primers that can be used for the cDNA/PCR/sequencing reactions for each locus are identified. As noted in the legend to Table II, some of the primer combinations shown represent alternatives which may be useful in confirming results for a particular locus which do not

30

fit with the expected sequences usually found with the rest of the haplotype. Each cDNA/PCR reaction is usually performed in a separate tube. However, when using Type 1 primers, the cDNA/PCR reactions for all the 5 loci (DRB, DQA, DQB, DPA and DPB) can be performed simultaneously in the same tube. The products of each locus are sequenced in separate tubes. Following the conditions described in the above protocol, the sequence ladders between the sequencing primer and the 5' 10 amplification primer could be clearly read starting from 2 to 14 bases from the sequencing primer binding site. No anomalous amplification products or sequencing ladders were detectable upon direct sequence analysis of amplified DRB, DQB1 and DQA1 cDNAs from the 43 15 homozygous cell lines tested (Table IIIA). The specific alleles at each Class II HLA locus composing the haplotypes carried by each of these cell lines are shown in Table IIIB. The number of ladders generated for each cell line was always that expected according to the 20 specificity of the amplification primers (one DQB1 and one DQA1 ladder for all cell lines, one DRB ladder for DR1 and DRw8 cell lines and two DRB ladders for haplotypes of the DRw52 and DRw53 supertypic groups).

Thus, analysis of the homozygous typing cell lines 25 showed that the Type 1 primers used for cDNA synthesis, PCR and sequencing reactions allowed for accurate amplification and sequencing of all the tested alleles at each of these loci.

30

fit with the expected sequences usually found with the rest of the haplotype. Each cDNA/PCR reaction is usually performed in a separate tube. However, when using Type 1 primers, the cDNA/PCR reactions for all the 5 loci (DRB, DQA, DQB, DPA and DPB) can be performed simultaneously in the same tube. The products of each locus are sequenced in separate tubes. Following the conditions described in the above protocol, the sequence ladders between the sequencing primer and the 5' 10 amplification primer could be clearly read starting from 2 to 14 bases from the sequencing primer binding site. No anomalous amplification products or sequencing ladders were detectable upon direct sequence analysis of amplified DRB, DQB1 and DQA1 cDNAs from the 43 15 homozygous cell lines tested (Table IIIA). The specific alleles at each Class II HLA locus composing the haplotypes carried by each of these cell lines are shown in Table IIIB. The number of ladders generated for each cell line was always that expected according to the 20 specificity of the amplification primers (one DQB1 and one DQA1 ladder for all cell lines, one DRB ladder for DR1 and DRw8 cell lines and two DRB ladders for haplotypes of the DRw52 and DRw53 supertypic groups).

Thus, analysis of the homozygous typing cell lines 25 showed that the Type 1 primers used for cDNA synthesis, PCR and sequencing reactions allowed for accurate amplification and sequencing of all the tested alleles at each of these loci.

30

31

**TABLE IIIA**  
**Cell Lines and Heterozygote Combinations Tested**

Cell Line	Class II HLA Type	Subject	Class II HLA Types**
SA	DR1-Dw1	S1	DR1-Dw1/DRw17
MZ070782	DR1-Dw20	S2	DR1-Dw1/DR4-Dw4
KAS011	DRw16-Dw21	S3	DR1-Dw7/DRw8.1
*CALCGERO	DRw16-Dw-	S4	DRw15-Dw2/DRw17
*WJR076	DRw16-Dw21	S5	DRw15-Dw2/DR4-
Dw4			
*DEM	DRw16-Dw21/DR4	S6	DRw16-Dw21/DRw17
WT24	DRw16-Dw21	S7	DR5x6/DRw17
RML	DRw16-Dw22	S8	*DRw13-
Dw18/DRw17			
SCHU	DRw15-Dw2	S9	DRw13-Dw19/DRw17
WT8	DRw15-Dw2	S10	DR4-Dw4/DRw17
*AMAI	DRw15-Dw2	S11	DR4-Dw4/DRw12
E4	DRw15-Dw12	S12	DR4-Dw13/DR1-Dw1
MT14B	DR4-Dw14	S13	DR4-Dw13/DRw17
EJ32B	DRw17-SYD3	S14	DR4-Dw14/DRw15-
Dw2			
RSH	DRw18-DwRSH	S15	*DR4-Dw15/DRw17
DEU	DR4-Dw4	S16	DRw11-Dw5/DRw17
WT51	DR4-Dw4	S17	DRw12/DR1-Dw1
JBAF	DR4-Dw13	S18	DRw12/DRw8.1
YAR	DR4-Dw10	S19	*DRw14-Dw9/DRw17
KT17	DR4-DKT2	S20	DR7/DRw17
SPCC010	DRw11-DB2	S21	DR4-Dw4/DR7
JBUSH	DRw11-Dw5	S22	DRw8.1/DR5x6@
TISTI	DRw11-DwTISTI	S23	DRw8.1/DRw11-Dw5
JVM	DRw11-DwJVM	S24	DRw8.2/DRw11-Dw5
BM16	DRw12-DB6	S25	DRw8.3/DR1-Dw1
*HO301	DRw13-Dw19	S26	DRw8.3/DRw15-Dw2
WDV	DRw13-Dw18	S27	DR9/DR1-Dw1
WT47	DRw13-Dw19		
TEM	DRw14-Dw9		
EK	DRw14-Dw9		
AMALA	DRw14-Dw16		
LBF	DR7-DB1		
BH	DR7-DB1		
CF96	DR7-Dw7		
BER	DR7-Dw7		
DBB	DR7-Dw11		
MOU	DR7-Dw17		
BTB	DRw8-Dw8.1		
OLGA	DRw8-Dw8.2		
LIVY	DRw8-Dw8.3		
TAB089	DRw8-Dw8.3		
DKB	DR9-Dw23		

characterized homozygous cell lines unless indicated (\*).

\* Haplotypes carrying new allelic sequences (DRB1, DRB3, DQA1 or DQB1 loci).

\* Only the tested heterozygote combinations are listed. The remainder of the 40 subjects tested were homozygotes or carried the haplotypes listed in this table.

@ This DRB specificity (DR5x6) has been given this arbitrary designation according to serological, RFLP and sequence information.

32

The allelic composition at DRB, DQA1 and DQB1 loci for the sequenced haplotypes corresponded to that expected according to published sequence information from well

**Table IIIb**  
**Allotypic Composition of Human Class II Haplotypes**

Haplotype	WSI	DRB1	DRB2	DRB4	DRB5	DRB6	DQA1
DR1-Dw1	9001	*0101	-	-	-	*0501	*0101
#DR1-Dw20	9002	*0102	-	-	-	*0501*	*0101
DR4-Dw21	9009	*84,-15	*1601	-	*0201	*0502	*0102
#DR16-Dw21	9012	9007	*1601	-	*0502	*0502	*0102
DR46-Dw22	9016	-	*1602	-	*0502	*0501	*0501
DR45-Dw2	9013	9017	*1501	-	*0101	*0502	*0102
#DR415-Dw2	9010	-	*1501	-	-1.3	*0502	*0102
DR415-Dw12	9011	-	*1502	-	*0102	*0501	*0103
DR417-Dw3	9018	-	*0301	*0101	-	*0501	*1501
DR417-DwSYD	9015	-	*0301	*0201	-	*0201	*0501
DR418-DwSH	9021	-	*0302	*0101	-	*0201	*0401
DR4-Dw6	9025	*0401	-	-	-	*0301	*0301
DR4-Dw4	9039	*0401	-	-	-	*0302	*0301
DR4-Dw13	9030	-	*0403	-	-	*0301	*0301
DR4-DRB2	9024	-	*0403/6	-	*0101	*0302	*0301
DR4-Dw10	9026	-	*0402	-	*0101	*0302	*0301
DR4-Dw14	9028	-	*0404	-	*0101	*0302	*0301
DR4-Dw15 KT3 (a)	9038	-	*0405	-	*0101	*0301	*0301
# - CC	9045	-	-	*0101	-	*0201	*0301
DR411-DB2	9036	-	*1104	*0201	-	*0502	*0102
DR411-Dw5	9035	-	*1101	*0201	-	*0301	*0501
DR411-Dw1	9042	-	*1103	*0201	-	*0301	*0501
DR411-Dw7YM	9049	-	*1102	*0201	-	*0301	*0501
DR412-DB6	9038	-	*1201	-	-	*0301	*0501
# - 586	DR585	-	*0101	-	-	*0301	*0501
#DR413-Dw19	9055	-	*1302	*0301	-	DRB6.5	*0102
DR413-Dw18	9062	-	*1301	*0101	-	*0603	*0103
DR413-Dw18 (b)	-	-	*1301	*0101	-	*0502	*0102
DR413-Dw19	9063	-	*1302	*0301	-	*0604	*0102
DR414-Dw9	9057	9054	*1401	*0201	-	*0503	DOA1.4
# - MA	-	-	*1401	*0201	-	DOB5.4	ND
DR414-Dw16	9064	-	*1402	*0101	-	*0501	*0501
DR7-DB1	9096	9046	*0701	-	*0101	*0201	*0201
DR7-Dw7	9094	9093	*0701	-	*0101	*0201	*0201
DR7-Dw11	9052	-	*0701	-	*0101&	*0303	*0201
DR7-Dw17	9050	-	*0701	-	*0101	*0201	*0201
DR48-Dw8.1	9067	-	*0801	-	-	*0402	*0401
DR48-Dw8.2	9071	-	*0802	-	-	*0402	*0401
DR48-Dw8.3	9070	-	*0803	-	-	*0301	*0601
DR48-Dw8.3	9066	-	*0803	-	-	*0601	*0103
DR9-Dw23	9075	-	*0901	-	*0101	*0303	*0301
DRw10 (c-e)	-	-	*1001	-	-	*0501	*0101

The allelic composition at DRB, DQA1 and DQB1 loci for the sequenced haplotypes corresponded to that expected according to published sequence information from well characterized homozygous cell lines unless indicated (\*).

\* Haplotypes carrying new allelic sequences (DRB1, DRB3, DRB4 or DQB1 loci).

\* Only the tested heterozygote combinations are listed.

\* Only the tested subjects tested were homozygotes or carried the haplotypes listed in this table.

@ This DRB specificity (DR5x6) has been given this arbitrary designation according to serological, RFLP and sequence information.

-----

2. Amplification and Direct Sequencing of DQA1 and DQB1 cDNAs in Subjects of Unknown HLA Type

DNA sequences have been determined for most HLA Class II allelic specificities defined by conventional HLA typing techniques (March, S.G.E., Bodmer, J.G., HLA-DRB nucleotide sequences, 1990. *Immunogenetics* 31:141, 1990; Todd, J.A., Bell, J.I., McDeferritt, H.O.: HLA-DQB gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. *Nature* 329:559, 1987). Comparisons of these sequences indicates that any given DQA1 or DQB1 homozygous or heterozygous allelic combination is characterized by a specific sequencing ladder.

Total RNA from PBMCs from 40 different subjects was tested to evaluate if the allelic composition of DQA1 and DQB1 homo- and heterozygotes could be determined correctly by direct amplification and sequencing using Type 1 primers. These subjects had been previously serologically typed but the typing information was not known to the investigator who assigned the Class II allelic specificities from the sequencing results. These 40 subjects comprised 27 different heterozygote combinations (Table III). All individuals were assigned DQA1 and DQB1 allelic sequences that were consistent with the serological phenotypes. In all the heterozygotes tested, both allelic sequences could be read clearly from the composite sequence pattern. A unique pattern is found for every particular heterozygote combination in the same way that certain RFLP banding patterns correspond to certain heterozygote allelic combinations. For instance, in a DQB2/DQB1.1 heterozygote one would find the sequence GGG(A/T)T(A)CCGGC(A/G) at codons 45 to 49 which can only be attributed to that particular allele combination. In practice, interpretation of heterozygous sequence ladders is initiated by reading certain polymorphic positions where allele-specific bases may be found, such as, for instance, the second

35

36

base of codon 46, where DQB1\*0201 is the only allele that has an A. The sequences of the two possible templates are then deduced and compared with the sequences of all known alleles at the different loci.

In Figure 3 we show the overlapping ladder corresponding to a DQB1\*0201/DQB1\*0302 Heterozygote; interpretation of the pattern is indicated on the side of the ladder. The absence of expected bands or the presence of unexpected bands for a particular allele or allelic combination is therefore suggestive of sequence heterogeneity, i.e., new alleles. The same can be said for DPA1 and DPB1 typing when appropriate primer combinations are used (Table III). For instance, substitution of the A at the second base of codon 46 would strongly suggest the presence of a sequence variant of DQB1\*0201. Once detected, the sequence of the variant can be confirmed after selective amplification of the variant or by subcloning the amplified products.

20

3. Amplification and Direct Sequencing of DRB cDNAs From Subjects of Unknown HLA Type

As described above, the use of Type 1 primers allows the unambiguous sequencing of all heterozygous combinations of DQA1 and DQB1 alleles. The same can be said for DPA1 and DPB1 typing when appropriate primer combinations are used (Table II). Because of the isotypic complexity of DRB genes (expression of more than one DRB locus by certain haplotypes), amplification and sequencing of cDNAs from DRB heterozygotes with Type 1 primers can generate up to four overlapping ladders, thus generating complex sequencing patterns. DRB cDNAs from the same 40 individual tested above for DQA1 and DQB1 genes were amplified and sequenced using DRB-specific Type 1 primers. As mentioned above, these 40 individuals comprised 27 different heterozygote combinations, including several examples from each of the groups of complex DRB allelic

35

35

37

combinations which would generate up to four sequencing ladders. The DRB sequence ladders generated with Type 1 primers were analyzed as described above for DQ<sub>A1</sub> and DQ<sub>B1</sub> loci: highly polymorphic positions were analyzed first for the presence of bands unique to specific alleles or groups of alleles (i.e., DR4) and the sequences deduced and compared with the sequences of all known alleles at all loci. As example, in Figure 3 we show the ladder generated by sequencing a complex DRB heterozygote (four overlapping ladders); the positions with two or more bands are indicated on the side of the figure and assigned to each of the allelic types composing the complex sequencing pattern. For all but one sample, the information deduced from these sequencing experiments matched the independently determined serological phenotypes of the subject under study as well as the DQ<sub>A1</sub> and DQ<sub>B1</sub> allelic types assigned to these individuals by direct sequencing of these genes as described above. The inconsistent sample had been serologically typed as DRw13/DRw4 but was typed by sequence analysis as DRw13/DRw8-Dw8.1. The presence of a DRB1\*0801 allele instead of a DRB1\*0401 allele was confirmed in a repeated experiment; we thus believe that the serological typing was in error. In all the 40 cases, all DQ<sub>B1</sub>, DQ<sub>A1</sub> and DRB1 templates had been equally amplified and sequenced with a similar efficiency by the use of Type 1 primers. DRB3, DRB4 and DRB5 sequence ladders could be read in all but one case (a DRB3\*0101 [DRw52a] sequence was not initially observed in a DRW13/DRW17 heterozygote). Since DRB3\*0101 is in linkage disequilibrium with DRB1\*0301, the former allele was expected to be found in the overlapping ladder as well. In order to rule out the possibility of an error, the investigator assigning the HLA types from the sequencing ladders repeated the typing of this individual; the DRB3\*0101 could be read in the repeated experiment.

38

Although the results generated by the use of Type 1 primers were compatible with the serological phenotypes, the exclusive use of Type 1 primers will not allow in all cases to assign each of the specific ladders to each of the expressed loci in all possible heterozygotes. Given below are the most complex situations which cannot be addressed by the exclusive use of Type 1 primers: 1) distinction among the different DR4 allelic sequences in certain heterozygotes since they differ by only a few nucleotide base pairs and such differences could be masked by the presence of additional ladders; 2) to distinguish between DRB1\*1601 and DRB1\*1502 since their sequence differences will be masked by those of their linked DRB5 alleles; 3) to distinguish between DRB1\*1301 and DRB1\*1302 (which only differ at codon 86 since this difference can also be masked by other ladders; and finally 4) distinction between DRB1\*0301 and DRB1\*0302 in specific heterozygote combinations.

20 We have thus developed a more informative strategy to deal with DRB; this strategy, which consists of the additional use of non-conserved (Type 2) primers permits the clear elucidation of even the most complex combination of the four DRB sequences that might be present in an individual. These non-conserved primers, as opposed to allele-specific primers, are designed to be used in reactions performed simultaneously with the reactions using Type 1 primers and aim at selectively amplifying certain ladders from the complex sequencing patterns without requiring previous typing information.

25 Analysis of the sequence variability of the second exon of the DRB genes has allowed us to identify two regions which could be used to design non-conserved (Type 2) primers: 1) codons 5-13; and 2) codons 29-35. The sequence of the former region follows a group-specific sequence pattern, i.e., a sequence shared by groups of alleles at individual loci. The latter region

30 DRB3\*0101 is in linkage disequilibrium with DRB1\*0301, the former allele was expected to be found in the overlapping ladder as well. In order to rule out the possibility of an error, the investigator assigning the HLA types from the sequencing ladders repeated the 35 typing of this individual; the DRB3\*0101 could be read in the repeated experiment.

39

exhibits a scattered nucleotide polymorphism in DRB1 and DRB3, DRB4 and DRB5 genes. We designed five different non-conserved primers annealing to these two polymorphic regions: 1) DRB23 (specific for DR2-DRB1 ladders); 2) DRB24 (specific for DRw17-, DRw18-, DRw13-, DRw14-, DRw11-, DRw12-, and DRw8- DRB1 ladders); 3) DRB25 (specific for DR4- DRB1 ladders); 4) DRB16 and 5) DRB17, the latter two primers annealing to the second region of moderate polymorphism (from 1 to 5 nucleotides different among the known alleles for each locus) (Tables I and IV). Because of the different nature and distribution of mismatches between these primers and the different DRB templates, the type of templates amplified selectively by these primers will be different. Each of the first three primers will amplify up to two DRB1 cDNAs in any given heterozygote and will not amplify any DRB3, DRB4 or DRB5 cDNAs. On the contrary, the use of primers DRB16 and DRB17 will allow the random selective amplification of certain transcripts from DRB1, DRB3, DRB4 and/or DRB5 loci in most heterozygote combinations. We therefore tested these primers in order to determine which combination would give the best discriminatory results for DRB typing. Furthermore, since the sequences of these primers carry from 0-12 mismatches with the sequences of the known DRB alleles at the different DRB loci, their use allowed us to determine the number of mismatches between the primers and each of the possible cDNAs that are required to obtain such selective amplification of DRB transcripts. The specific combinations of primers used for the CDNA/PCR/sequencing reactions are shown in Table II above. The results of this analysis are shown below.

40

	*0101-3	*1501	*1502	*1401-2	*1401-2	*0301/1301-2	*0401-8	*1101-4	*0801-3	*1201	*0701
DRB1	0	4	5	4	5	4	0	4	3	4	5
DRB16	4	5	4	4	5	4	0	4	3	4	5
DRB21	6	6	6	6	6	6	0	6	6	6	6
DRB22	5	5	5	5	5	5	0	5	5	5	5
DRB23	5	5	5	5	5	5	0	5	5	5	5
DRB24	5	5	5	5	5	5	0	5	5	5	5
DRB25	5	5	5	5	5	5	0	5	5	5	5
DRB16	1	1	1	1	1	1	0	1	1	1	1
DRB17	2	2	2	2	2	2	0	2	2	2	2
DRB23	3	3	3	3	3	3	0	3	3	3	3
DRB24	4	4	4	4	4	4	0	4	4	4	4
DRB25	5	5	5	5	5	5	0	5	5	5	5
DRB1	0901	*1001	DRB5#	DRB3+0101	DRB3*0201	DRB3+0301	DRB4				
				DRB3/DRB4/DRB5							

TABLE IIIA. Mismatches between Type 2 DRB-primers and DRB alleles at different loci.

And/or Non-Allelic DRB Transcripts

Primers and DRB alleles to the Selective Amplification of Alleles

Contribution of Nucleotide Base Mismatches Between 5' Amplicons

TABLE IV

25 sequences of these primers carry from 0-12 mismatches with the sequences of the known DRB alleles at the different DRB loci, their use allowed us to determine the number of mismatches between the primers and each of the possible cDNAs that are required to obtain such selective amplification of DRB transcripts. The specific combinations of primers used for the

20 CDNA/PCR/sequencing reactions are shown in Table II above. The results of this analysis are shown below.

41

**TABLE V**  
**Selective Amplification of DRB and DQB1 cDNAs**  
**In Combinations of Alleles Mismatches with**  
**Type 2 Oligonucleotides (#)**

Haplotypes	Selected Alleles	Do Primer
DRB1*1301, DRB3*0101/DRB1*1601, DRB5*0201	DRB1*1601	DRB16
DRB1*1301, DRB3*0101/DRB1*0801	DRB1*0801	DRB16
DRB1*1601/DRB3*0101/DRB1*1601, DRB5*0201	DRB1*1601	DRB16
DRB1*1601/DRB3*0101/DRB1*0801	DRB1*0801	DRB16
DRB5*02, DRB3*0101/DRB1*0801	DRB3*0101	DRB17
DRB5*06, DRB3*0101/DRB1*0301/DRB3*0101	DRB3*0101	DRB16
DRB1*1101, DRB3*0201/DRB1*1501, DRB5*0101	DRB3*0201	DRB16
DRB1*1101, DRB3*0201/DRB1*1501, DRB5*0101	DRB5*0101	DRB17*
DRB1*1201, DRB3*0201/DRB1*1101, DRB3*0201	DRB1*1101	DRB16
DRB1*1201, DRB3*0201/DRB1*1101, DRB3*0201	DRB3*0201	DRB17
DRB1*1605, DRB3*0101/DRB1*0301/DRB3*0101	DRB1*0405 + DRB4*0101	DRB16
DRB1*1605, DRB3*0101/DRB1*1101, DRB3*0201	DRB1*1101 + DRB5*6	DRB16
DRB1*1501, DRB3*0101	DRB1*1501	DRB16
DRB1*1601, DRB3*0201/DRB1*0401, DRB4*0101	DRB1*0401 + DRB5*0201	DRB16**
DRB1*1601, DRB3*0201/DRB1*0401, DRB4*0101	DRB1*0401 + DRB1*0401	DRB16
DRB1*1601, DRB3*0201	DRB1*1601	DRB16
DRB1*1602, DRB3*0202	DRB1*1602	DRB16
DRB1*0401, DRB4*0101	DRB4*0101	DRB16
DQB1*0604/DQB1*0502	DQB6	DQB6
DQB1*0301/DQB1*0101	DQB1*0301	DQB6
DQB1*0101/DQB1*0101	DQB1*0501	DQB14
DQB1*0201/DQB1*0603	DQB1*0201	DQB6
DQB1*0604/DQB1*0301	DQB1*0604	DQB5
DQB1*0301/DQB1*0502	DQB1*0301	DQB6
DQB1*0603/DQB1*0101	DQB1*0603	DQB6
DQB1*0501	DQB1*0501	DQB14
DQB1*0201/DQB1*0101	DQB1*0201	DQB14
DQB1*0201/DQB1*0302	DQB1*0201	DQB6
DQB1*0201/DQB1*0502	DQB1*0201	DQB6

(#) In this Table we only show representative examples of haplotypic combinations lacking those alleles the primers are fully matched with, for reasons of simplicity (see Table IV). Whenever these primers were used in heterozygotes carrying the alleles they specifically recognize, these alleles were selectively amplified. Note that in the examples shown in the Table the non-conserved primers selectively amplified the templates closer in sequence to the primer. The DRB and DQB1 alleles composing these haplotypes are shown under "haplotypes". The selected alleles and the primers used are indicated in the two other columns. More than one individual

was tested for some of the heterozygote combinations listed in this Table.

\* DRB5\*0101 and DRB3\*0201 templates both have one mismatch with primer DRB117. Selection of DRB5\*0101 could be related to the differential positioning of the mismatch with respect to the primer.

\*\* A weaker DRB4\*0101 template was also observed.

These primers were able to selectively amplify certain DRB templates in all the heterozygous combinations tested. In heterozygotes carrying the alleles these primers are matched with, these alleles were selectively amplified; 5 in heterozygotes not carrying the alleles specifically recognized by the primers, the DRB templates which had the fewest base pair mismatches with the primers were selectively amplified in the PCR. Specific examples of the latter are shown in Table V and Figure 4. As shown in Table V, Type 2 primers could differentially amplify DRB transcripts from the combinations of allelic cDNAs that differ from each other in as few as one nucleotide substitution, provided that high stringency annealing conditions are used for the PCR (annealing at 55°C). For example, in the heterozygote combination DRW13/DRW8-Dw8.1, the DRB1\*0801 allele (3 mismatches with the primer) was selected over DRB1\*1301 and DRB3\*0101 genes (each has 4 mismatches with the primer) by the DRB16 oligonucleotide primer. Although DRB3\*0101 or DRB3\*0201 and DRB5\*0101 genes all harbour one mismatch with primer DRB17, this oligonucleotide selected the DRB5\*0101 sequence in a DRW11/DRW15 heterozygote (Table V). It is possible that the differential positioning of the mismatches within the sequence recognized by the oligonucleotide also has an influence on the stability of the primer/cDNA complex and hence on the outcome of the PCR.

25

\* DRB5\*0101 and DRB3\*0201 templates both have one mismatch with primer DRB117. Selection of DRB5\*0101 could be related to the differential positioning of the mismatch with respect to the primer.

20

\*\* A weaker DRB4\*0101 template was also observed.

25

43

The ability of non-conserved primers to select certain alleles in heterozygote combinations was also tested for DQB1 genes (Table V). As with DRB-specific "Type 2" primers, the use of high temperatures (55°C) in the annealing step of the PCR was required for achieving the selective amplification of single DQB1 alleles in heterozygotes with non-conserved primers. For instance, when annealing of primer DQB6 was allowed to proceed at 37°C in cDNAs from a DQB1\*0301/DQB1\*0501 and a DQB1\*0201/DQB1\*0603 heterozygote, both alleles in both heterozygotes were equally amplified. At 55°C, the allele with the most homologous sequence to the 5' primer, was amplified over the other in the PCR. Combinations of alleles both differing from the primer in two nucleotides but in different relative position were also differentially amplified with a non-conserved primer. For instance, primer DQB6 selected the DQB1\*0604 sequence in a DQB1\*0604/DQB1\*0502 heterozygote (Table V). Five nucleotides separate the two mismatches between the DQB1\*0604 allele and the DQB6 primer, whereas only two nucleotides separate the 20 mismatches between the DQB1\*0502 and the primer. These results clearly indicate that the oligonucleotide primers annealing to polymorphic regions at the 5' end of the target cDNAs can be tailored to achieve a reproducible selective amplification of a limited number of DRB or DQB templates in complex heterozygous combinations.

Although the use of Type 1 primers allows the unambiguous sequencing of all possible DQA, DQB, DPA and DPB heterozygotes, such an approach will not give absolute discriminatory information for all DRB Heterozygotes. We 25 have shown that the simultaneous use of Type 1 and Type 2 primers for DRB will permit the clear elucidation of even the most complex of all DRB heterozygote combinations. When DRB-SBR is used for typing purposes, we perform three Type 2-reactions (using DRB23, 24 and 25) simultaneously with a Type 30 1-reaction (Table II). The simultaneous use of these

44

reactions using these primers has the highest discriminatory power for complete DRB typing in a single run and allows the identification of novel sequence heterogeneity. Only one Type 1 reaction is required for DQB1, one for DQA1, one for DPA1 and one for DPB1 (Table II).

### EXAMPLE III

#### Determining Unknown HLA Type of Subjects by Direct Sequencing of the Second Exon of Class II Genes

- Routine HLA typing of large populations of individuals for sequence polymorphisms can be performed by the use of the methodology reported here which can also identify previously unknown allelic variants. Figures 2A and 2B show a flow-chart for the routine protocol used to determine sequence allelism of individuals of unknown HLA types.
1. Employment of Primer Combinations for cDNA, PCR and Direct Sequencing Using RNA as Initial Template  
For synthesizing cDNA molecules, the present invention provides single strand DNA anti-sense oligonucleotide primers that anneal to conserved regions of the gene mRNAs to be reverse transcribed, amplified and sequenced. These oligonucleotide primers include an oligonucleotide sequence that: (1) anneals to a conserved region (codons 105 through 111) shared by all the alleles at all the DRB loci, the latter being DRB1, DRB3, DRB4 and DRB5, respectively (e.g., primer DRB20). Four simultaneous cDNA reactions (one per tube) are performed for DRB typing, all 20 using primer DRB20 (reactions A, B, C and D in Table II and Figure 2A); (2) anneals to a conserved region (codons 105 through 111) shared by all the alleles at the DQB locus (e.g., primer DQB7) (reaction E in Table II and Figure 2A); (3) anneals to a conserved region (codons 147 through 157) shared 25 by all the alleles at the DQA locus (e.g. primer DQA9)
  - 20
  - 25
  - 30
  - 35

45

(reaction F in Table II and Figure 2A); (4) anneals to a conserved region (codons 105 through 111) shared by all the alleles at the DPB locus (e.g. primer DPB11) (reaction G in Table II and Figure 2A); (5) anneals to a conserved region (codons 104 through 110) shared by all the alleles at the DPA locus (e.g. primer DPA14) (reaction H in Table II and Figure 2A); (6) anneals to a conserved region (codons 222 through 228) shared by all the alleles at the DPA locus (e.g. primer DPA19) (reaction I in Table II and Figure 2A). The specific oligonucleotides added to each of these reactions once the cDNA synthesis is done in order to amplify and sequence the products are indicated below as well as in Table II and in Figure 2.

To amplify cDNA molecules corresponding to each expressed DRB loci of each chromosome (DRB1 and DRB3 or DRB4 or DRB5, depending on the haplotype -isotypic complexity-), a conserved oligonucleotide primer which anneals to codons -32 to -26 (e.g. oligonucleotide DRB11) is added to one of the four tubes where the cDNA synthesis reactions corresponding to DRB genes took place. The combination of the cDNA synthesis reaction primer and the newly added conserved primer is used to amplify all the alleles at all DRB loci expressed by a given individual. Each of the remaining three tubes containing DRB cDNA products receives one of three different non-conserved oligonucleotides (also called Type 2) annealing to codons 7-13 (e.g. primer DRB23), 5-11 (e.g. primer DRB24), 6-13 (e.g. primer DRB25), respectively. Each non-conserved primer is designed to favor the amplification of cDNAs corresponding to different groups of alleles at the DRB1 locus. Comparison of the sequencing ladders generated by these four reactions allows complete and accurate interpretation of the sequences corresponding to each of the four possible DRB genes expressed by a given individual (one or two for each of the parental chromosomes).

46

For the DQB1 locus, a conserved oligonucleotide primer which anneals to codons 1-7 of the DQB cDNAs (e.g. primer DQB13) can be used for amplifying each of the DQB1 genes expressed in any given individual (one for each parental chromosome). In the case of the DQA1 locus, a conserved single strand DNA oligonucleotide primer useful for amplifying each of the DQA1 genes expressed in any given subject anneals to codons -10 to -4 of the DQA1 cDNA (e.g. primer DQA10). For the DPB1 locus, a conserved oligonucleotide (e.g. primer DPB10) annealing to codons -19 to -13, is used to amplify each of the expressed DPB1 genes in any given subject. For DPA1 locus, a conserved oligonucleotide (e.g. primer DPA15) annealing to codons -23 to -17, is used to amplify each of the expressed DPA1 genes in a given subject. In a separate reaction, conserved primer DPA18, annealing to codons 59-65 of the DPA1 cDNAs is used in combination with the cDNA Primer DPA19 to amplify each of the expressed DPA1 genes in any individual. This second DPA1 reaction is targeted at a second polymorphic region of this gene.

Primers useful in direct sequencing the polymerase chain reaction products corresponding to DRB loci include an anti-sense oligonucleotide primer (e.g. DRB12) annealing to codons 87-94 of all the alleles at DRB loci; this primer is used for sequencing the products generated by the first of the four DRB reactions. For direct sequencing the polymerase chain reaction products generated with the other three DRB reactions, an anti-sense oligonucleotide annealing to codons 97-103 of all the alleles at DRB1 locus can be used (e.g. primer DRB30). The use of a different sequencing oligonucleotide in these three DRB reactions allows reading of downstream polymorphic regions of DRB1 genes not seen in the first DRB reaction which uses the example sequencing primer DRB12. Primers useful in direct sequencing the polymerase chain reaction products corresponding to DQB1

(reaction F in Table II and Figure 2A); (4)

anneals to codons 1-7 of the DQB cDNAs (e.g. primer DQB13) can be used for amplifying each of the DQB1 genes expressed in any given individual (one for each

parental chromosome). In the case of the DQA1 locus, a conserved single strand DNA oligonucleotide primer useful for amplifying each of the DQA1 genes expressed in any given

subject anneals to codons -10 to -4 of the DQA1 cDNA (e.g. primer DQA10). For the DPB1 locus, a conserved

oligonucleotide (e.g. primer DPB10) annealing to codons -19 to -13, is used to amplify each of the expressed DPB1 genes in any given subject. For DPA1 locus, a conserved

oligonucleotide (e.g. primer DPA15) annealing to codons -23 to -17, is used to amplify each of the expressed DPA1 genes in a given subject. In a separate reaction, conserved primer

DPA18, annealing to codons 59-65 of the DPA1 cDNAs is used in combination with the cDNA Primer DPA19 to amplify each of the expressed DPA1 genes in any individual. This second DPA1 reaction is targeted at a second polymorphic region of this

gene.

Primers useful in direct sequencing the polymerase chain reaction products corresponding to DRB loci include an anti-sense oligonucleotide primer (e.g. DRB12) annealing to codons 87-94 of all the alleles at DRB loci; this primer is used for sequencing the products generated by the first of the four DRB reactions. For direct sequencing the polymerase chain reaction products generated with the other three DRB reactions, an anti-sense oligonucleotide annealing to codons 97-103 of all the alleles at DRB1 locus can be used (e.g. primer DRB30). The use of a different sequencing

oligonucleotide in these three DRB reactions allows reading of downstream polymorphic regions of DRB1 genes not seen in the first DRB reaction which uses the example sequencing primer DRB12. Primers useful in direct sequencing the

polymerase chain reaction products corresponding to DQB1

(reaction F in Table II and Figure 2A); (4)

anneals to codons 1-7 of the DQB cDNAs (e.g. primer DQB13) can be used for amplifying each of the DQB1 genes expressed in any given individual (one for each

parental chromosome). In the case of the DQA1 locus, a conserved single strand DNA oligonucleotide primer useful for amplifying each of the DQA1 genes expressed in any given

subject anneals to codons -10 to -4 of the DQA1 cDNA (e.g. primer DQA10). For the DPB1 locus, a conserved

oligonucleotide (e.g. primer DPB10) annealing to codons -19 to -13, is used to amplify each of the expressed DPB1 genes in any given subject. For DPA1 locus, a conserved

oligonucleotide (e.g. primer DPA15) annealing to codons -23 to -17, is used to amplify each of the expressed DPA1 genes in a given subject. In a separate reaction, conserved primer

DPA18, annealing to codons 59-65 of the DPA1 cDNAs is used in combination with the cDNA Primer DPA19 to amplify each of the expressed DPA1 genes in any individual. This second DPA1 reaction is targeted at a second polymorphic region of this

gene.

Primers useful in direct sequencing the polymerase chain reaction products corresponding to DRB loci include an anti-sense oligonucleotide primer (e.g. DRB12) annealing to codons 87-94 of all the alleles at DRB loci; this primer is used for sequencing the products generated by the first of the four DRB reactions. For direct sequencing the polymerase chain reaction products generated with the other three DRB reactions, an anti-sense oligonucleotide annealing to codons 97-103 of all the alleles at DRB1 locus can be used (e.g. primer DRB30). The use of a different sequencing

oligonucleotide in these three DRB reactions allows reading of downstream polymorphic regions of DRB1 genes not seen in the first DRB reaction which uses the example sequencing primer DRB12. Primers useful in direct sequencing the

polymerase chain reaction products corresponding to DQB1

47

locus include an anti-sense oligonucleotide primer (e.g. DQB5) annealing to codons 78-83 of all the alleles at this locus. Direct sequencing of polymerase chain reaction products corresponding to DQA1 locus include an anti-sense oligonucleotide primer (e.g. DQA29) annealing to codons 88-95 of all the alleles at this locus. Direct sequencing of polymerase chain reaction products corresponding to DPB1 locus include a sense oligonucleotide primer (e.g. DPB13) annealing to codons 12/-5 of all the alleles at this locus.

For direct sequencing of polymerase chain reaction products for the DPA1 reaction which used primers DPA14 and DPA15, an anti-sense oligonucleotide annealing to codons 88-94 of all the alleles at this locus can be used (e.g. primer DPA16).

For direct sequencing of polymerase chain reaction products for the DPA1 reaction which used primers DPA19 and DPA18, an anti-sense oligonucleotide annealing to codons 214-220 of all the alleles at this locus can be used (e.g. primer DPA20).

## 2. Employment of Primer Combinations for PCR and Direct Sequencing Using DNA Templates

To amplify DNA molecules corresponding to each DRB loci of each chromosome a conserved anti-sense oligonucleotide primer annealing to base pairs 18-38 of intron 3 (e.g. oligonucleotide DRB1406) is added to each of four PCR reaction tubes (reactions S, V, T and U in Table II and Figure 2B). Each of these four tubes will receive a different additional oligonucleotide annealing to codons -4 to +3 (e.g. primer DRB22), to codons 7-13 (e.g. primer DRB23), 5-11 (e.g. primer DRB24), 6-13 (e.g. primer DRB25), respectively. The first reaction is used to amplify all the alleles at all DRB loci carried by a given individual. Each of the remaining three reactions is designed to favor the amplification of DNA corresponding to different groups of alleles at the DRB1 locus. As with RNA templates, comparison of the sequencing ladders generated by these four reactions

48

allows complete and accurate interpretation of the sequences corresponding to each of the four possible DRB genes expressed by a given individual (one or two for each of the parental chromosomes).

- 5 For the DQB1 locus, two conserved oligonucleotide primers which anneal to codons 88-94 (e.g. primer DQB932) and 11-17 (e.g. primer DQB931) or 1-7 (e.g. primer DQB13) can be used for amplifying each of the DQB1 genes carried by any given individual (one for each parental chromosome) (reaction 10 W in Table II and Figure 2B). For the DPB1 locus, two conserved oligonucleotides (a primer, e.g. DPB14, annealing to base pairs -42 to -62 of intron 2, and a primer e.g. DPB15, annealing base pairs 39-59 of intron 3) are used to amplify each of the DPB1 genes carried by any given subject (reaction X in Table II and Figure 2B). For DPA1 locus a conserved oligonucleotide such as DPA10 (annealing to base pairs -69 to -50 of intron 2) and DPA11 (annealing to base pairs 55-71 of intron 3) are used to amplify each of the DPA1 genes carried by a given subject (reaction Y in Table II and Figure 2B).
- 15 Primers useful in direct sequencing the Polymerase chain reaction products generated from DNA templates corresponding to DRB loci include an anti-sense oligonucleotide primer (e.g. DRB12) annealing to codons 87-94 of all alleles at DRB loci; this primer is used for sequencing the products generated by the first of the four DRB reactions. For direct sequencing the polymerase chain reaction products generated with the other three DRB reactions, a sense oligonucleotide annealing to codons 39-46 of all the alleles at DRB locus can be used (e.g. primer DRB1400). The use of a different sequencing oligonucleotide in these three DRB reactions allows reading of downstream polymorphic regions of DRB1 genes not seen in the first DRB reaction which uses the example sequencing primer DRB12.
- 20 Primers useful in direct sequencing the polymerase chain

49

reaction products corresponding to DQB1 locus include an anti-sense oligonucleotide primer (e.g. DQB5) annealing to codons 78-83 of all the alleles at this locus. Direct sequencing of polymerase chain reaction products for corresponding to DPB1 locus include an anti-sense oligonucleotide primer (e.g. DPB16) annealing to base pairs 1-21 of intron 3 of all the alleles at this locus. FOR direct sequencing of polymerase chain reaction products for the DPA1 reaction an anti-sense oligonucleotide annealing to codons 76-82 of all the alleles at this locus can be used (e.g. primer DPA12).

Procedure for Determining Unknown HLA Type

A subject of unknown HLA type, diseased or not, is 15 to be typed for Class II HLA polymorphism. From 10 to 50 mL of peripheral blood are drawn. The peripheral blood mononuclear cells are prepared by centrifugation over Ficoll-Hypaque gradients. The cells are then lysed in guanidium isothiocyanate and total cellular RNA prepared using conventional methods (either by centrifugation on cesium chloride gradients, which lasts about 16 hours, or by the guanidium isothiocyanate-phenol-chlorophorm extraction method, which can be performed in less than 4 hours. See Gouuh, *Sudra* (1988); Johns et al., *Anal. Biochem.*, 180:276 20 (1989). Otherwise genomic DNA from these cells or other sources (hair, blood stains, sperm, etc.) can be prepared with conventional methods such as provided by Higuchi, R. in PCR Technology, Erlich, M. (ed.), Stockton Press:31 (1989). DQB1, DQA1, DRB (DRB1, DRB3/4/5), DP1 and DPB1 cDNA molecules are synthesized from total RNA using locus-specific primers. Approximately, one microgram of RNA is reverse transcribed with MOLVRT (reverse transcriptase) and DRB (CQDRB20), DQB (CQDQB7), DQA (CQDQ9), DPB (DPB11) and DPA (DPA14, DPA19) (optional) -specific non-sense primers in a 20 uL final volume reaction (30-60 minute incubation). The

50

reaction for each Class II gene is performed in a different tube, but they can be performed in the same tube if preferred. For routine purposes, four simultaneous reactions are performed for DRB, one for DQB, one for DQA1, one for DPB1, and two for DPA1 gene products.

Once these reactions are completed, the enzymatic amplification of the respective cDNA molecules is then performed by directly adding to the 20 uL reverse transcription reaction, the reagents needed for the amplification step. Alternatively, if DNA is used, the primer combinations used for the PCR are those shown in Table II herein (the anti-sense primers as well as the sense primers will be different). This includes the PCR reagents and appropriate conserved and non-conserved oligonucleotide primers. This example uses four reactions for DRB (tubes 1, 15 2, 3 and 4), one for DQB (tube 5), one for DQA (tube 6), one for DPB (tube 7), and two for DPA (tubes 8 and 9, respectively). Reactions 2, 3 and 4 incorporate primers DRB23, DRB24 and DRB25, respectively. For rapid typing (in 20 less than 24 hours), the latter are the preferred combinations. Alternative combinations of the primers that can be used are shown in Table II.

Once completed, the reactions are spun-dialyzed for about 15 minutes using Centricon (Amicon, Ultrafree (millipore)) or similar columns to remove unincorporated primers and dNTPs. The retentate or one half of the recovered 25 retentate for each reaction is then directly sequenced using Taq polymerase and the primers described in Table II for each combination of primers used in the cDNA/PCR reactions using 30 P-32 end-labeled (10 minutes) locus-specific sequencing primers (35 minutes).

The sequencing reactions products are loaded on an acrylamide gel, electrophoresed in 2-3 hours and exposed to X-ray films for 4-12 hours. The gels are read and results from

1

gels are compared to nucleotide sequences corresponding to all possible alleles.

Comparisons can be made visually using the naked eye or using a personal computer and a software package including the nucleotide sequences of all alleles of all haplotypes and routines which indicate how the comparison is to be performed as well as subroutines which will allow identification of new allelic sequences.

10

SEQUENCE LISTING

Santamaria, Pedro  
Boyce-Jacino, Michael T.  
Barbosa, Jose J.  
Rich, Stephen S.  
Faras, Anthony J.

## TITLE OF INVENTION: DNA Sequence-Based HLA

(iii) NUMBER OF SEQUENCES : 49

**CORRESPONDENCE ADDRESS:**

(A) ADDRESSEE:  
 (B) STREET:  
 (C) CITY:  
 (D) STATE:  
 (E) COUNTRY:  
 (F) ZIP:

## COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Dis  
 (B) COMPUTER: 720  
 (C) OPERATING SYSTEM: Nor  
 (D) SOFTWARE: Wor

CURRENT APPLICATION DATE

(C) CLASSIFICATION:

(A) NAME: Kowalchy  
(B) REGISTRATION NUMBER:  
(C) REFERENCE/DOCKET NO:

(A) TELEPHONE: (612) 332-5300  
(B) TELEFAX: (612) 332-9081

三

-53-

## (2) INFORMATION FOR SEQUENCE ID NO: 1:

- 5 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear
- 10 (ii) MOLECULE TYPE: Genomic DNA  
 10 (iv) ANTI-SENSE: Yes  
 (v) FRAGMENT TYPE: Internal Fragment  
 15 (vi) ORIGINAL SOURCE: Synthetically Derived  
 (ix) FEATURE:  
 (A) NAME/KEY: Oligonucleotide Primer DQB7  
 (B) LOCATION: Anneals to codons 105 to  
 111 of the DQB1 transcript of HLA  
 class II

SEQUENCE DESCRIPTION: SEQ ID NO: 1:  
 G GTG GAT GGC CTC TGT CC 21

- 20 (xi) (v) FRAGMENT TYPE: Internal Fragment  
 (A) NAME/KEY: Oligonucleotide Primer DQB7  
 (B) LOCATION: Anneals to codons 105 to  
 111 of the DQB1 transcript of HLA  
 class II
- 25 (xii) SEQUENCE DESCRIPTION: SEQ ID NO: 1:  
 G GTG GAT GGC CTC TGT CC 21

- 30 (xiii) (v) FRAGMENT TYPE: Internal Fragment  
 (A) NAME/KEY: Oligonucleotide Primer DQA9  
 (B) LOCATION: Anneals to codons 148 to  
 155 of the DQA1 transcript of HLA  
 class II
- 35 (xiv) SEQUENCE DESCRIPTION: SEQ ID NO: 2:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

- 40 (xv) MOLECULE TYPE: Genomic DNA  
 (iv) ANTI-SENSE: Yes  
 (v) FRAGMENT TYPE: Internal Fragment  
 (vi) ORIGINAL SOURCE: Synthetically Derived  
 (A) NAME/KEY: Oligonucleotide Primer DRB20  
 45 (xvi) (v) FRAGMENT TYPE: Internal Fragment  
 (vi) ORIGINAL SOURCE: Synthetically Derived  
 (A) NAME/KEY: Oligonucleotide Primer DRB20

- 50 (xvii) (v) FRAGMENT TYPE: Internal Fragment  
 (vi) ORIGINAL SOURCE: Synthetically Derived  
 (A) NAME/KEY: Oligonucleotide Primer DRB20  
 55 (xviii) (v) FRAGMENT TYPE: Internal Fragment  
 (vi) ORIGINAL SOURCE: Synthetically Derived  
 (A) NAME/KEY: Oligonucleotide Primer DRB20

-54-

## (2) INFORMATION FOR SEQUENCE ID NO: 3:

- 5 (xi) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear
- 10 (ii) MOLECULE TYPE: Genomic DNA  
 10 (iv) ANTI-SENSE: Yes  
 (v) FRAGMENT TYPE: Internal Fragment  
 15 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 22 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

SEQUENCE DESCRIPTION: SEQ ID NO: 2:  
 GTG CTG CAG GGG CTG GGT CTT 21

- 20 (ii) MOLECULE TYPE: Genomic DNA  
 (iv) ANTI-SENSE: Yes  
 (v) FRAGMENT TYPE: Internal Fragment  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 22 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

- 25 (iii) (ii) MOLECULE TYPE: Genomic DNA  
 (iv) ANTI-SENSE: Yes  
 (v) FRAGMENT TYPE: Internal Fragment  
 (vi) ORIGINAL SOURCE: Synthetically Derived  
 (A) NAME/KEY: Oligonucleotide Primer DQA9  
 30 (ix) FEATURE:  
 (A) NAME/KEY: Oligonucleotide Primer DQA9

- 35 (x) (ii) MOLECULE TYPE: Genomic DNA  
 (iv) ANTI-SENSE: Yes  
 (v) FRAGMENT TYPE: Internal Fragment  
 (vi) ORIGINAL SOURCE: Synthetically Derived  
 (A) NAME/KEY: Oligonucleotide Primer DRB20  
 40 (xi) (ii) MOLECULE TYPE: Genomic DNA  
 (iv) ANTI-SENSE: Yes  
 (v) FRAGMENT TYPE: Internal Fragment  
 (vi) ORIGINAL SOURCE: Synthetically Derived  
 (A) NAME/KEY: Oligonucleotide Primer DRB20

- 45 (xii) (ii) MOLECULE TYPE: Genomic DNA  
 (iv) ANTI-SENSE: Yes  
 (v) FRAGMENT TYPE: Internal Fragment  
 (vi) ORIGINAL SOURCE: Synthetically Derived  
 (A) NAME/KEY: Oligonucleotide Primer DRB20  
 50 (xiii) (ii) MOLECULE TYPE: Genomic DNA  
 (iv) ANTI-SENSE: Yes  
 (v) FRAGMENT TYPE: Internal Fragment  
 (vi) ORIGINAL SOURCE: Synthetically Derived  
 (A) NAME/KEY: Oligonucleotide Primer DRB20

- 55 (xv) (ii) MOLECULE TYPE: Genomic DNA  
 (iv) ANTI-SENSE: Yes  
 (v) FRAGMENT TYPE: Internal Fragment  
 (vi) ORIGINAL SOURCE: Synthetically Derived  
 (A) NAME/KEY: Oligonucleotide Primer DRB20

-54-

-55-

(i.i) MOLECULE TYPE: Genomic DNA

(i.iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: Internal Fragment

(vi) ORIGINAL SOURCE: Synthetically Derived

(ix) FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
DQB1.3(B) LOCATION: Anneals to codons 1 to 7 of  
the DQB1 transcript of HLA class II

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

AGA GAC TCT CCC GAG GAT TGC  
Arg Asp Ser Pro Glu Asp Phe  
1 5

(10) INFORMATION FOR SEQUENCE ID NO: 5:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

5

(i.i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs  
(B) TYPE: Nucleic Acid  
(C) STRANDEDNESS: Single  
(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Genomic DNA

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: Internal Fragment

(vi) ORIGINAL SOURCE: Synthetically Derived

(2) INFORMATION FOR SEQUENCE ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs  
(B) TYPE: Nucleic Acid  
(C) STRANDEDNESS: Single  
(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Genomic DNA

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: Internal Fragment

(vi) ORIGINAL SOURCE: Synthetically Derived

(ix) FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
DRB11(B) LOCATION: Anneals to codons -33 to -  
26 of the DRB1, DRB3, DRB4 and DRB5  
transcripts of HLA class II

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

20

(ii) MOLECULE TYPE: Genomic DNA

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: Internal Fragment

25

(2) INFORMATION FOR SEQUENCE ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs  
(B) TYPE: Nucleic Acid  
(C) STRANDEDNESS: Single  
(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Genomic DNA

(iv) ANTI-SENSE: no

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

(i.i) MOLECULE TYPE: Genomic DNA

(i.iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: Internal Fragment

(vi) ORIGINAL SOURCE: Synthetically Derived

(ix) FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
DRB22(B) LOCATION: Anneals to codons -4 to +3  
of the DRB1, DRB3, DRB4 and DRB5  
transcripts of HLA class II

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

5

(ii) MOLECULE TYPE: Genomic DNA

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: Internal Fragment

(vi) ORIGINAL SOURCE: Synthetically Derived

(2) INFORMATION FOR SEQUENCE ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs  
(B) TYPE: Nucleic Acid  
(C) STRANDEDNESS: Single  
(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Genomic DNA

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: Internal Fragment

50

(2) INFORMATION FOR SEQUENCE ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs  
(B) TYPE: Nucleic Acid  
(C) STRANDEDNESS: Single  
(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Genomic DNA

(iv) ANTI-SENSE: no

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

(i.i) MOLECULE TYPE: Genomic DNA

(i.iv) ANTI-SENSE: no

-56-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

(i.i) MOLECULE TYPE: Genomic DNA

(i.iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: Internal Fragment

(vi) ORIGINAL SOURCE: Synthetically Derived

(ix) FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
Leu Ala Leu Ala Gly Asp Thr  
-1 1(B) LOCATION: Anneals to codons 1 to 7 of  
the DQB1 transcript of HLA class II

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

21

(ii) MOLECULE TYPE: Genomic DNA

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: Internal Fragment

(vi) ORIGINAL SOURCE: Synthetically Derived

(2) INFORMATION FOR SEQUENCE ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs  
(B) TYPE: Nucleic Acid  
(C) STRANDEDNESS: Single  
(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Genomic DNA

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: Internal Fragment

55

(2) INFORMATION FOR SEQUENCE ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs  
(B) TYPE: Nucleic Acid  
(C) STRANDEDNESS: Single  
(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Genomic DNA

(iv) ANTI-SENSE: no

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

(i.i) MOLECULE TYPE: Genomic DNA

(i.iv) ANTI-SENSE: no

-57-

-57-

(v) FRAGMENT TYPE: Internal Fragment  
 (vi) ORIGINAL SOURCE: Synthetically Derived  
 FEATURE:  
 (A) NAME/KEY: Oligonucleotide Primer  
 DQA10

5 (ix) (B) LOCATION: Anneals to Codons -10 to -4  
 of the DQA1 transcript of HLA class II

SEQUENCE DESCRIPTION: SEQ ID NO: 7:

CITG TCC TCC GTC GTC ATG AGC CC  
 Leu Thr Thr Val Met Ser Pro  
 -10 -5

10 (xi) (2) INFORMATION FOR SEQUENCE ID NO: 8:  
 SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

15 (ii) MOLECULE TYPE: Genomic DNA  
 ANTI-SENSE: no

SEQUENCE DESCRIPTION: SEQ ID NO: 7:

CITG TCC TCC GTC GTC ATG AGC CC  
 Leu Thr Thr Val Met Ser Pro  
 -10 -5

20 (iii) (2) INFORMATION FOR SEQUENCE ID NO: 9:  
 SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

25 (iv) ANTI-SENSE: yes  
 (v) FRAGMENT TYPE: Internal Fragment  
 (vi) ORIGINAL SOURCE: Synthetically Derived  
 FEATURE:  
 (A) NAME/KEY: Oligonucleotide Primer  
 DQB932

30 (ix) (B) LOCATION: Anneals to codons 88 to 94  
 of the DQB1 transcript of HLA class II

SEQUENCE DESCRIPTION: SEQ ID NO: 8:

TGG CCT CTG CAG GGT CGC GCG  
 21

35 (x) (2) INFORMATION FOR SEQUENCE ID NO: 10:  
 SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

40 (xi) (2) INFORMATION FOR SEQUENCE ID NO: 10:  
 SEQUENCE CHARACTERISTICS:  
 (A) NAME/KEY: Oligonucleotide Primer  
 DQB931

45 (ii) (B) LOCATION: Anneals to codons 88 to 94  
 of the DQB1 transcript of HLA class II

50 (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 8:  
 TGG CCT CTG CAG GGT CGC GCG  
 21

55 (iv) (2) INFORMATION FOR SEQUENCE ID NO: 9:  
 SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

(v) ANTI-SENSE: yes  
 (vi) FRAGMENT TYPE: Internal Fragment  
 (vii) ORIGINAL SOURCE: Synthetically Derived

-58-

(2) INFORMATION FOR SEQUENCE ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Genomic DNA

(iii) ANTI-SENSE: no

(iv) FRAGMENT TYPE: Internal Fragment

(v) ORIGINAL SOURCE: Synthetically Derived

(vi) FEATURE:

(vii) (A) NAME/KEY: Oligonucleotide Primer  
 DQB931(viii) (B) LOCATION: Anneals to codons 88 to 94  
 of the DQB1 transcript of HLA class II

(ix) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

(x) TGG CCT CTG CAG GGT CGC GCG

(xi) 21

(1) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Genomic DNA

(iii) ANTI-SENSE: yes

(iv) FRAGMENT TYPE: Internal Fragment

(v) ORIGINAL SOURCE: Synthetically Derived

(vi) FEATURE:

(vii) (A) NAME/KEY: Oligonucleotide Primer  
 DQB932(viii) (B) LOCATION: Anneals to codons 88 to 94  
 of the DQB1 transcript of HLA class II

(ix) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

(x) TGG CCT CTG CAG GGT CGC GCG

(xi) 21

(1) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Genomic DNA

(iii) ANTI-SENSE: yes

(iv) FRAGMENT TYPE: Internal Fragment

(v) ORIGINAL SOURCE: Synthetically Derived

(vi) (A) NAME/KEY: Oligonucleotide Primer  
 DQB931(vii) (B) LOCATION: Anneals to codons 88 to 94  
 of the DQB1 transcript of HLA class II

(viii) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

(x) TGG CCT CTG CAG GGT CGC GCG

(xi) 21

(1) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Genomic DNA

(iii) ANTI-SENSE: yes

(iv) FRAGMENT TYPE: Internal Fragment

(v) ORIGINAL SOURCE: Synthetically Derived

(vi) (A) NAME/KEY: Oligonucleotide Primer  
 DQB932(vii) (B) LOCATION: Anneals to codons 88 to 94  
 of the DQB1 transcript of HLA class II

(viii) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

(x) TGG CCT CTG CAG GGT CGC GCG

(xi) 21





-63-

## (2) INFORMATION FOR SEQUENCE ID NO: 17:

## (1) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: Internal Fragment

(vi) ORIGINAL SOURCE: Synthetically Derived  
 FEATURE:(ix) (A) NAME/KEY: Oligonucleotide Primer  
 DRB1\*01401(B) LOCATION: Anneals to codons 98 to 104  
 of the DRB1\*0701-2 transcript of HLA  
 class II

SEQUENCE DESCRIPTION: SEQ ID NO: 17:

GAG GTG ACT GTG TAT CCT GAC 21  
 Glu Val Thr Val Tyr Pro Asp  
 100

## 35 (2) INFORMATION FOR SEQUENCE ID NO: 18:

## (1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: Internal Fragment

(vi) ORIGINAL SOURCE: Synthetically Derived  
 FEATURE:(A) NAME/KEY: Oligonucleotide Primer  
 DQB1\*0202

55 (ii) MOLECULE TYPE: Genomic DNA

-64-

(B) LOCATION: Anneals to codons 142 to  
 148 of the DRB1, DRB3, DRB4 and DRB5  
 transcripts of HLA class II5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:  
 GAT CAG GCC TGT GGA CAC CAC 21

10

## (2) INFORMATION FOR SEQUENCE ID NO: 19:

## (1) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

(iv) ANTI-SENSE: Yes

(v) FRAGMENT TYPE: Internal Fragment

(vi) ORIGINAL SOURCE: Synthetically Derived

(xi) FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
 DQB1\*0303(B) LOCATION: Anneals to codons 127 to  
 133 of the DRB1, DRB3, DRB4 and DRB5  
 transcripts of HLA class II20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:  
 CCG GAA CCA CCT GAC TTC AAT 21

30 (ix) FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
 DQB1\*0303(B) LOCATION: Anneals to codons 127 to  
 133 of the DRB1, DRB3, DRB4 and DRB5  
 transcripts of HLA class II35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:  
 CCG GAA CCA CCT GAC TTC AAT 21

45 (ix) FEATURE:

(A) MOLECULE TYPE: Genomic DNA

(2) INFORMATION FOR SEQUENCE ID NO: 20:

## (1) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Genomic DNA

11

			(iv)	ANTI-SENSE: no
			(v)	FRAGMENT TYPE: Internal Fragment
5			(vi)	ORIGINAL SOURCE: Synthetically Derived
			(ix)	FEATURE:
10				(A) NAME/KEY: Oligonucleotide Primer DQB1406
				(B) LOCATION: Anneals to bp18-38 to intron 33 of the DRB1, DRB3, DRB4 and DRB5 transcripts of HLA class II
15				SEQUENCE DESCRIPTION: SEQ ID NO: 20: GCCAAAGACTG GGCCCTCCAG C
				21
25			(2) INFORMATION FOR SEQUENCE ID NO: 21:	
			(i)	SEQUENCE CHARACTERISTICS:
				(A) LENGTH: 21 base pairs (B) TYPE: Nucleic Acid (C) STRANDEDNESS: Single (D) TOPOLOGY: Linear
				MOLECULE TYPE: Genomic DNA
			(ii)	ANTI-SENSE: Yes
			(iv)	FRAGMENT TYPE: Internal Fragment
			(v)	ORIGINAL SOURCE: Synthetically Derived
			(vi)	FEATURE:
30				(A) NAME/KEY: Oligonucleotide Primer DRBB25
				(B) LOCATION: Anneals to codons 79 to 85 of the DRB1, DRB3, DRB4 and DRB5 transcripts of HLA class II
				SEQUENCE DESCRIPTION: SEQ ID NO: 21: AAC CCC GTA GTT GTC TCT GCA
35				21
40				
45				
50				

(iv)	ANTI-SENSE: no			
(v)	FRAGMENT TYPE: Internal Fragment			
5 (vi)	ORIGINAL SOURCE: Synthetically Derived			
(ix)	FEATURE:			
10 (A)	NAME/KEY: Oligonucleotide Primer DQB1406			
(B)	LOCATION: Anneals to pp18'38' to intron 33 of the DRB1, DRB3, DRB4 and DRB5 transcripts of HLA class II			
15 (xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 20:  GCCAGAGCTG GGCCTCCAG C	21		
20 (x)				
25 (2)	INFORMATION FOR SEQUENCE ID NO: 21:			
(1)	SEQUENCE CHARACTERISTICS:			
30 (ii)	(A) LENGTH: 21 base Pairs (B) TYPE: Nucleic Acid (C) STRANDEDNESS: Single (D) TOPOLOGY: Linear			
35 (iv)	MOLECULE TYPE: Genomic DNA ANTI-SENSE: Yes			
(v)	FRAGMENT TYPE: Internal Fragment			
40 (vi)	ORIGINAL SOURCE: Synthetically Derived			
(ix)	FEATURE:			
45 (A)	NAME/KEY: Oligonucleotide Primer DRE825			
(B)	LOCATION: Anneals to codons 79' to 85' of the DRB1, DRB3, DRB4 and DRB5 transcripts of HLA class II			
50 (xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 21:  AAC CCC GTA GTT GTG TCT GCA	21		
55 (v)				



-69-

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

TA CTG ATG GPG CTG CTC ACA T  
 Leu Leu Met Val Ile Leu Thr Ser  
 -12 -5

- 5 (2) INFORMATION FOR SEQUENCE ID NO: 27:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear
- 10 (ii) MOLECULE TYPE: Genomic DNA  
 (iv) ANTI-SENSE: no  
 (v) FRAGMENT TYPE: Internal Fragment  
 (vi) ORIGINAL SOURCE: Synthetically Derived  
 (ix) FEATURE:  
 (A) NAME/KEY: Oligonucleotide Primer  
 DPB14
- 15 (B) LOCATION: Anneals to bp-42/-46 to  
 intron 2 of the DPB1 transcript of  
 HLA class II
- 20 (ii) SEQUENCE DESCRIPTION: SEQ ID NO: 28:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear
- 25 (ii) INFORMATION FOR SEQUENCE ID NO: 29:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear
- 30 (ii) MOLECULE TYPE: Genomic DNA  
 (iv) ANTI-SENSE: no  
 (v) FRAGMENT TYPE: Internal Fragment  
 (vi) ORIGINAL SOURCE: Synthetically Derived
- 35 (ii) SEQUENCE DESCRIPTION: SEQ ID NO: 27:  
 AGAGGGAAA AGAGGATTAG A  
 21
- 40 (2) INFORMATION FOR SEQUENCE ID NO: 28:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear
- 45 (ii) MOLECULE TYPE: Genomic DNA  
 (iv) ANTI-SENSE: no  
 (v) FRAGMENT TYPE: Internal Fragment  
 (vi) ORIGINAL SOURCE: Synthetically Derived
- 50 (2) INFORMATION FOR SEQUENCE ID NO: 30:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs
- 55 (ii) SEQUENCE DESCRIPTION: SEQ ID NO: 29:  
 CGGCCAAAG CCCTCACTCA C  
 21

-70-

## (xi) FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
 DPB15(B) LOCATION: Anneals to bp39-59 to  
 intron 3 of the DPB1 transcript of  
 HLA class II(xii) SEQUENCE DESCRIPTION: SEQ ID NO: 28:  
 GCCCTGGCA CGGGCCCGGC G  
 21

## (2) INFORMATION FOR SEQUENCE ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear(2) INFORMATION FOR SEQUENCE ID NO: 29:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear(2) INFORMATION FOR SEQUENCE ID NO: 29:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear(2) INFORMATION FOR SEQUENCE ID NO: 30:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs

-71-

(B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

(i.i) ANTI-SENSE: no

(iv) FRAGMENT TYPE: Internal Fragment

(v) ORIGINAL SOURCE: Synthetically Derived

(vi) FEATURE:

(A) NAME/KEY: Oligonucleotide Primer DPB17

(B) LOCATION: Anneals to bp-6/-26 to Intron 2 of the DPB1 transcript of HLA class II

SEQUENCE DESCRIPTION: SEQ ID NO: 30:  
 CGCTCATGTC CGCCCCCTCC C

(2) INFORMATION FOR SEQUENCE ID NO: 31:  
 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

(ii) ANTI-SENSE: yes

(v) FRAGMENT TYPE: Internal Fragment

(vi) ORIGINAL SOURCE: Synthetically Derived

(A) NAME/KEY: Oligonucleotide Primer DPB14

(B) LOCATION: Anneals to codons 104 to 110 of the DPB1 transcript of HLA class II

(2) INFORMATION FOR SEQUENCE ID NO: 33:  
 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

(ii) ANTI-SENSE: yes

(v) FRAGMENT TYPE: Internal Fragment

-72-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:  
 GTC AAT GTG GCA GAT GAG GGT

(2) INFORMATION FOR SEQUENCE ID NO: 32:  
 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Genomic DNA

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: Internal Fragment

(vi) ORIGINAL SOURCE: Synthetically Derived

(ix) FEATURE:

(A) NAME/KEY: Oligonucleotide Primer DPB15

(B) LOCATION: Anneals to codons -17 to -23 of the DPB1 transcript of HLA class II

CAT ATC AGA GCT GTG ATC TTG

(2) INFORMATION FOR SEQUENCE ID NO: 33:  
 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Genomic DNA

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: Internal Fragment

(vi) ORIGINAL SOURCE: Synthetically Derived

(ix) FEATURE:

(A) NAME/KEY: Oligonucleotide Primer DPB15

(B) LOCATION: Anneals to codons -17 to -23 of the DPB1 transcript of HLA class II

CAT ATC AGA GCT GTG ATC TTG

(2) INFORMATION FOR SEQUENCE ID NO: 35:  
 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Genomic DNA

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: Internal Fragment

(vi) ORIGINAL SOURCE: Synthetically Derived

(x) FEATURE:

(A) NAME/KEY: Oligonucleotide Primer DPB14

(B) LOCATION: Anneals to codons 104 to 110 of the DPB1 transcript of HLA class II

(2) INFORMATION FOR SEQUENCE ID NO: 37:  
 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Genomic DNA

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: Internal Fragment

-73-

(vi) ORIGINAL SOURCE: Synthetically Derived

(ix) FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
DPA16(B) LOCATION: Anneals to codons 88 to 94  
of the DPA1 transcript of HLA class  
II

SEQUENCE DESCRIPTION: SEQ ID NO: 33:

CTT GGG AAA CAC GGT CAC CTC 21

## (2) INFORMATION FOR SEQUENCE ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs  
(B) TYPE: Nucleic Acid  
(C) STRANDEDNESS: Single  
(D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

(vi) ORIGINAL SOURCE: Synthetically Derived

(ix) FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
DPA17(B) LOCATION: Anneals to codons -3 to -9  
of the DPA1 transcript of HLA class  
II

SEQUENCE DESCRIPTION: SEQ ID NO: 34:

CTG CTG AGT CTC CGA GGA GCT 21  
Leu Leu Ser Leu Arg Gly Ala  
-5(A) NAME/KEY: Oligonucleotide Primer  
DPA11

55

-74-

(2) INFORMATION FOR SEQUENCE ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs  
(B) TYPE: Nucleic Acid  
(C) STRANDEDNESS: Single  
(D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

(vi) ORIGINAL SOURCE: Synthetically Derived

FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
DPA10(B) LOCATION: Anneals to bp-69/-50 of  
intron 2 of the DPA1 transcript of  
HLA class II

SEQUENCE DESCRIPTION: SEQ ID NO: 35:

CTCTAGCTTT GACCACTGCC 20

(2) INFORMATION FOR SEQUENCE ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs  
(B) TYPE: Nucleic Acid  
(C) STRANDEDNESS: Single  
(D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

(vi) ORIGINAL SOURCE: Synthetically Derived

FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
DPA11(A) NAME/KEY: Oligonucleotide Primer  
DPA11

55

-75-

(B) LOCATION: Anneals to bp55-71 to inttron 3 of the DPAl transcript of HLA class II

SEQUENCE DESCRIPTION: SEQ ID NO: 36:

AGTCAGGG TGGCAGAG G 21

(B) LOCATION: Internal Fragment

ORIGINAL SOURCE: Synthetically Derived

FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
DPA18

(2) INFORMATION FOR SEQUENCE ID NO: 37:

SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: yes

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetically Derived

FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
DPA12

(B) LOCATION: Anneals to codons 76 to 82 of the DPAl transcript of HLA class II

SEQUENCE DESCRIPTION: SEQ ID NO: 37:

GGC CTG AGT GTG GTT GGA ACG 21

(B) LOCATION: Anneals to codons 59 to 65 of the DPAl transcript of HLA class II

FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
DPA19

(B) LOCATION: Anneals to codons 222 to 228 of the DPAl transcript of HLA class II

FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
GTC

(B) LOCATION: Anneals to codons 39 to 55 of the DPAl transcript of HLA class II

FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
GTC

-76-

(2) INFORMATION FOR SEQUENCE ID NO: 38:

SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetically Derived

SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: yes

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetically Derived

SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

(2) INFORMATION FOR SEQUENCE ID NO: 39:

SEQUENCE DESCRIPTION: SEQ ID NO: 21:

GTC CCC CTG GGC CCG GGG GTC 21

FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
GTC

-77-

(2) INFORMATION FOR SEQUENCE ID NO: 40:

SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: yes

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetically Derived

SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: yes

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetically Derived

SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: yes

(2) INFORMATION FOR SEQUENCE ID NO: 41:

SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: yes

(2) INFORMATION FOR SEQUENCE ID NO: 42:

SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: yes

-77-

WO 92/15711

-78-

- 5 (2) INFORMATION FOR SEQUENCE ID NO: 40:
- 5 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 21 base pairs
  - (B) TYPE: Nucleic Acid
  - (C) STRANDEDNESS: Single
  - (D) TOPOLOGY: Linear
- 10 (ii) MOLECULE TYPE: Genomic DNA
- 15 (iv) ANTI-SENSE: yes
- (v) FRAGMENT TYPE: Internal Fragment
- 20 (vi) ORIGINAL SOURCE: Synthetically Derived
- (ix) FEATURE:
- (A) NAME/KEY: Oligonucleotide Primer DPA2<sub>1</sub>
- 25 (B) LOCATION: Anneals to codons 214 to 220 of the DPA1 transcript of HLA Class II
- 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:
- ```
GCC AGA ACG CAG AGA CTT TAT 21
```
- 35 (2) INFORMATION FOR SEQUENCE ID NO: 41:
- 40 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 21 base pairs
  - (B) TYPE: Nucleic Acid
  - (C) STRANDEDNESS: Single
  - (D) TOPOLOGY: Linear
- 45 (ii) MOLECULE TYPE: Genomic DNA
- (iv) ANTI-SENSE: no
- (v) FRAGMENT TYPE: Internal Fragment
- 50 (vi) ORIGINAL SOURCE: Synthetically Derived
- (ix) FEATURE:
- (A) NAME/KEY: Oligonucleotide Primer DPA2<sub>1</sub>
- 5 (B) LOCATION: Anneals to codons 68 to 74 of the DPA1 transcript of HLA Class II
- 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:
- ```
AAC TTG AAT ACC TTG ATC CAG 21
Asn Leu Asn Thr Leu Ile Gln
```
- 15
- 20 (2) INFORMATION FOR SEQUENCE ID NO: 42:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 base pairs
  - (B) TYPE: Nucleic Acid
  - (C) STRANDEDNESS: Single
  - (D) TOPOLOGY: Linear
- 25 (ii) MOLECULE TYPE: Genomic DNA
- 30 (iv) ANTI-SENSE: no
- (v) FRAGMENT TYPE: Internal Fragment
- 35 (vi) ORIGINAL SOURCE: Synthetically Derived
- (ix) FEATURE:
- (A) NAME/KEY: Oligonucleotide Primer DRB2<sub>3</sub>
- 40 (B) LOCATION: Anneals to codons 7 to 13 of the DRB1 transcript of HLA class II
- 45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:
- ```
TTC TTG CAG CAG GAT AAC TA 20
Phe Leu Gln Gln Asp Lys Tyr
```
- 50

-79-

## (2) INFORMATION FOR SEQUENCE ID NO: 43:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetically Derived

## (ix) FEATURE:

- 20 (A) NAME/KEY: Oligonucleotide Primer  
 DRB24  
 (B) LOCATION: Anneals to codons 5 to 11  
 of the DRB1 transcript of HLA class II

## SEQUENCE DESCRIPTION: SEQ ID NO: 43:

CCA CGT TTC TTG GAG TAC TCT  
 Pro Arg Phe Leu Gly Tyr Ser  
 5 10

## (2) INFORMATION FOR SEQUENCE ID NO: 44:

## (i) SEQUENCE CHARACTERISTICS:

- 40 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetically Derived

## (ix) FEATURE:

- 45 (A) NAME/KEY: Oligonucleotide Primer  
 DRB16  
 (B) LOCATION: Anneals to codons 29 to 35  
 of the DRB1, DRB3, DRB4 and DRB5  
 transcripts of HLA class II

## (2) INFORMATION FOR SEQUENCE ID NO: 45:

## (i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetically Derived

## (ix) FEATURE:

- 55 (A) NAME/KEY: Oligonucleotide Primer  
 DRB25  
 (B) LENGTH: 21 base pairs  
 (C) TYPE: Nucleic Acid

-80-

## (2) INFORMATION FOR SEQUENCE ID NO: 46:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetic Derived

## (ii) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetic Derived

## (iii) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetic Derived

## (iv) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetic Derived

## (v) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetic Derived

## (vi) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetic Derived

## (vii) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetic Derived

## (viii) SEQUENCE CHARACTERISTICS:

- 40 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetic Derived

## (ix) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetic Derived

## (x) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetic Derived

## (xi) SEQUENCE CHARACTERISTICS:

- 55 (A) LENGTH: 21 base pairs  
 (B) TYPE: Nucleic Acid

-81-

(C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear  
 MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetically Derived

FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
 DRB17

(B) LOCATION: Anneals to codons 29 to 35  
 of the DRB1, DRB3, DRB4 and DRB5  
 transcripts of HLA class II

SEQUENCE DESCRIPTION: SEQ ID NO: 46:

AGA TAC TTC CAT AAC CAG GAG  
 Arg Tyr Phe His Asn Gln Glu  
 21  
 30 35

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetically Derived

FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
 DQB14

(B) LOCATION: Anneals to codons -8 to -2  
 of the DQB1 transcript of HLA class  
 II

SEQUENCE DESCRIPTION: SEQ ID NO: 48:

CTG AGC TCC TCA CTG GCT GAG  
 Leu Ser Ser Ser Lys Ala Glu  
 21  
 -5

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetically Derived

FEATURE:

(A) NAME/KEY: Oligonucleotide Primer DQB6

(B) LOCATION: Anneals to codons -8 to -2  
 of the DQB1 transcript of HLA class  
 II

SEQUENCE DESCRIPTION: SEQ ID NO: 49:

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

-82-

(C) STRANDEDNESS: SEQ ID NO: 47:  
 (D) TOPOLOGY: Linear  
 MOLECULE TYPE: Genomic DNA

5

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetically Derived

FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
 DRB17

(B) LOCATION: Anneals to codons 29 to 35  
 of the DRB1, DRB3, DRB4 and DRB5  
 transcripts of HLA class II

SEQUENCE DESCRIPTION: SEQ ID NO: 46:

AGA TAC TTC CAT AAC CAG GAG  
 Arg Tyr Phe His Asn Gln Glu  
 21  
 30 35

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetically Derived

FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
 DQB14

(B) LOCATION: Anneals to codons -8 to -2  
 of the DQB1 transcript of HLA class  
 II

SEQUENCE DESCRIPTION: SEQ ID NO: 48:

CTG AGC TCC TCA CTG GCT GAG  
 Leu Ser Ser Ser Lys Ala Glu  
 21  
 -5

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetically Derived

FEATURE:

(A) NAME/KEY: Oligonucleotide Primer DQB6

(B) LOCATION: Anneals to codons -8 to -2  
 of the DQB1 transcript of HLA class  
 II

SEQUENCE DESCRIPTION: SEQ ID NO: 49:

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

(C) STRANDEDNESS: SEQ ID NO: 47:  
 (D) TOPOLOGY: Linear  
 MOLECULE TYPE: Genomic DNA

5

ANTI-SENSE: no

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetically Derived

FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
 DRB17

(B) LOCATION: Anneals to codons 29 to 35  
 of the DRB1, DRB3, DRB4 and DRB5  
 transcripts of HLA class II

SEQUENCE DESCRIPTION: SEQ ID NO: 46:

AGA TAC TTC CAT AAC CAG GAG  
 Arg Tyr Phe His Asn Gln Glu  
 21  
 30 35

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetically Derived

FEATURE:

(A) NAME/KEY: Oligonucleotide Primer  
 DQB14

(B) LOCATION: Anneals to codons -8 to -2  
 of the DQB1 transcript of HLA class  
 II

SEQUENCE DESCRIPTION: SEQ ID NO: 48:

CTG AGC TCC TCA CTG GCT GAG  
 Leu Ser Ser Ser Lys Ala Glu  
 21  
 -5

FRAGMENT TYPE: Internal Fragment

ORIGINAL SOURCE: Synthetically Derived

FEATURE:

(A) NAME/KEY: Oligonucleotide Primer DQB6

(B) LOCATION: Anneals to codons -8 to -2  
 of the DQB1 transcript of HLA class  
 II

SEQUENCE DESCRIPTION: SEQ ID NO: 49:

MOLECULE TYPE: Genomic DNA

ANTI-SENSE: no

-83-

- (v) FRAGMENT TYPE: Internal Fragment  
(vi) ORIGINAL SOURCE: Synthetically Derived
- 5 (ix) FEATURE:  
(A) NAME/KEY: Oligonucleotide Primer  
DQB1<sub>5</sub>
- 10 (B) LOCATION: Anneals to codons -8 to -2  
of the DQB1 transcript of HLA class  
II
- 15 SEQUENCE DESCRIPTION: SEQ ID NO: 49:  
CTG AGC ACC TCG GTG GCT GAG 21  
Leu Ser Thr Ser Val Ala Glu  
20 Leu Ser Thr Ser Val Ala Glu  
-5

Applicants state that the paper copy of the  
above "Sequence Listing" Section of the present  
25 application, and the computer readable form of the same  
submitted therewith, are the same.

## WHAT IS CLAIMED:

1. A method for determining a major histocompatibility complex genotype of a subject in a sample containing subject nucleic acid comprising:
  - (a) isolating nucleic acid from said sample;
  - (b) amplifying said nucleic acid by polymerase chain reaction to generate sufficient polymerase chain reaction product for each allele of said gene locus to be sequenced, all of said alleles for each gene locus and chromosome to be sequenced being amplified with at least one conserved oligonucleotide primer pair and at least one of said alleles for each gene locus and chromosome to be sequenced being amplified with at least one conserved oligonucleotide primer and at least one non-conserved oligonucleotide primer;
  - (c) sequencing directly each polymerase chain reaction product for each allele at each gene locus of each chromosome with Taq polymerase and a conserved primer specific for each locus that is sequenced; and
  - (d) analyzing each sequenced polymerase chain reaction product to determine the genotype of said subject.
2. The method of claim 1 wherein said isolated nucleic acid is genomic DNA.
3. The method of claim 1 wherein said isolated nucleic acid is RNA and further comprises the following step prior to amplifying said nucleic acid:
  - (a) synthesizing cDNA molecules for each allele of each gene locus to be sequenced, wherein said

84

85

synthesis employs a locus-specific oligonucleotide primer that anneals to a conserved region of each allele of each said gene locus.

4. The method of claim 1 wherein said major histocompatibility genotype to be determined is a HLA Class II genotype.

5. The method of claim 4 wherein said Class II gene locus to be sequenced is DQB1.

6. The method of claim 4 wherein said Class II gene locus to be sequenced is DQA1.

7. The method of claim 4 wherein said Class II gene loci to be sequenced are DRB 1/3/4/5.

8. The method of claim 4 wherein said Class II gene loci to be sequenced is DPA 1.

9. The method of claim 4 wherein said Class II gene loci to be sequenced is DPB 1.

10. The method of claim 1 wherein analyzing said sequenced polymerase chain reaction product involves comparing the nucleotide sequence of each allele of each gene locus sequenced to known sequences for each such gene locus followed by comparing the sequence of each allele of each gene locus amplified with a conserved/non-conserved oligonucleotide primer pair to the nucleotide sequence of each allele of such gene locus amplified with a conserved oligonucleotide primer pair.

86

11. The method of claim 1 wherein analyzing each polymerase chain reaction product to determine genotype is conducted with a computer having a program including nucleotide sequences of all alleles of all haplotypes for HLA Class II loci.

12. The method of claim 1 wherein said amplifying cDNA molecules with said conserved oligonucleotide primer includes annealing said conserved oligonucleotide primer to said cDNA at about 37°C.

13. The method of claim 1 wherein said amplifying cDNA molecules with said non-conserved primer includes annealing said non-conserved primer to said cDNA at about 55°C.

14. A method for determining the Class II histocompatibility genotype of a subject in a sample containing subject nucleic acid comprising:

- (a) isolating nucleic acid from said sample;
- (b) amplifying said nucleic acid by polymerase chain reaction to generate sufficient polymerase chain reaction product for each allele of said Class II gene locus to be sequenced, all of said alleles for each Class II gene locus and chromosome to be sequenced being amplified with at least one conserved oligonucleotide primer pair and at least one of said alleles for each Class II gene locus and chromosome to be sequenced being amplified with at least one conserved oligonucleotide primer and at least one non-conserved oligonucleotide primer;

- (c) sequencing directly each polymerase chain reaction product for each allele at each Class

87

- II gene locus of each chromosome with Taq polymerase and a conserved primer specific for each Class II locus that is sequenced; and determining the genotype of said subject by comparing the nucleotide sequence of each allele at each Class II locus sequenced to known sequences for each such Class II locus followed by comparing the sequence of each allele of each Class II locus amplified with a degenerated oligonucleotide primer to the nucleotide sequence of each allele of such Class II locus amplified with a conserved oligonucleotide primer.
15. The method of claim 14 wherein said isolated nucleic acid is RNA and further comprises the following step prior to amplifying said nucleic acid:
- (a) synthesizing cDNA molecules for each allele of each Class II gene locus to be sequenced, wherein said synthesis employs a locus-specific oligonucleotide primer that anneals to a conserved region of each allele of each said Class II gene locus.

16. A method for determining the Class II HLA genotype of a subject in a sample containing subject nucleic acid comprising:
- (a) isolating total cellular RNA from said sample;
  - (b) synthesizing cDNA molecules for each allele of at least one Class II gene locus to be sequenced, wherein said synthesis employs a locus-specific oligonucleotide primer that anneals to a conserved region of each allele of each said Class II gene locus;

- 88
- (c) amplifying said cDNA molecules by polymerase chain reaction to generate a polymerase chain reaction product for each allele of said Class II gene locus to be sequenced, all of said alleles for each Class II gene locus and chromosome to be sequenced being amplified with at least one conserved oligonucleotide primer pair and at least one of said alleles for each Class II gene locus and chromosome to be sequenced being amplified with at least one conserved oligonucleotide primer and at least one non-conserved oligonucleotide primer;
  - (d) sequencing directly each polymerase chain reaction product for each allele at each Class II gene locus of each chromosome with Taq polymerase and a conserved primer specific for each Class II locus that is sequenced to produce a nucleic acid sequence ladder for each allele; and
  - (e) analyzing each nucleic acid ladder to determine the genotype of said subject by comparing the nucleotide sequence of each allele of each Class II locus sequenced to known sequences for each such Class II locus followed by comparing the sequence of each allele of each Class II locus amplified with a conserved/non-conserved oligonucleotide primer pair to the nucleotide sequence of each allele of such Class II locus amplified with a conserved oligonucleotide primer pair.
17. The method of claim 16 wherein said Class II HLA genotype to be determined includes nucleotide sequences for the DRB1, DRB3, DRB4, DRB5, DQA1, DQB1, DPB1 and DPB1 genes of said subject.

89

90

18. An oligonucleotide primer comprising a single strand of DNA which anneals to codons 105 to 111 of the DQB transcript.

19. An oligonucleotide primer having the sequence GGTGGTGTAGGGCCnCTGTC. (SEQ. ID NO:1)

20. An oligonucleotide primer comprising a single strand of DNA which anneals to codons 1 to 7 of DQB.

21. An oligonucleotide primer having the sequence AGAGACTCTCCGAGGATTTC. (SEQ. ID NO:14)

22. An oligonucleotide primer comprising a single strand of DNA which anneals to codons 148 to 155 of its DQA transcript.

23. An oligonucleotide primer having the sequence GTGTGAGGTACTATCTTGAG. (SEQ. ID NO:3)

24. An oligonucleotide primer comprising a single strand of DNA which anneals to codons -10 to -4 of DQA cDNAs.

25. An oligonucleotide primer having the sequence CTGnOCTCCGAGATGAGCCC. (SEQ. ID NO:7)

26. An oligonucleotide primer comprising a single strand of DNA which anneals to codons 105 to 111 of DRB1 transcript.

27. An oligonucleotide primer having the sequence GTCGCTGAGGGCTGGGCTT. (SEQ. ID NO:2)

28. An oligonucleotide primer comprising a single strand of DNA which anneals to codons -33 to -26 of DRB1 transcripts.

29. An oligonucleotide primer having the sequence TGTnTCTCAGGATGGTGTTC. (SEQ. ID NO:6)

30. An oligonucleotide primer comprising a single strand of DNA which anneals to codons 7 to 13 of DRB1 transcript.

31. An oligonucleotide primer having the sequence TnCTGTGACGAGGATAAATA. (SEQ. ID NO:42)

32. An oligonucleotide primer comprising a single strand of DNA which anneals to codons 5 to 11 of DRB 1 transcript.

33. An oligonucleotide primer having the sequence CCACAGTGTCTCTGGAGTACTCT. (SEQ. ID NO:43)

34. An oligonucleotide primer comprising a single strand of DNA which anneals to codons 6 to 13 of DRB 1 transcript.

35. An oligonucleotide primer having the sequence TTTCTTGAGGAGGTAAACA. (SEQ. ID NO:44)

36. An oligonucleotide primer comprising a single strand of DNA which anneals to codons 105 to 111 of DPB transcript.

37. An oligonucleotide primer having the sequence GTTGnGGGTGCTGCACGGCCC. (SEQ. ID NO:24)

91

38. An oligonucleotide primer comprising a single strand of DNA which anneals to codons 222 to 228 of DPA transcript.

39. An oligonucleotide primer having the sequence GTCGCCCTGGCCCGGGGGTC. (SEQ. ID NO:39)

40. An oligonucleotide primer comprising a single strand of DNA which anneals to codons -19 to -13 of DPB transcript.

41. An oligonucleotide primer having the sequence CGGACAGCTGGCTCTGACGGCG. (SEQ. ID NO:23)

42. An oligonucleotide primer comprising a single strand of DNA which anneals to codons -23 to -17 of DPA transcript.

43. An oligonucleotide primer sequence of CATAATCAGAGCTGTAATCTTG. (SEQ. ID NO:32)

44. An oligonucleotide primer comprising a single strand of DNA which anneals to codons 59 to 65 of DPA transcript.

45. An oligonucleotide primer having the sequence CTGGGCTAACATGCTATATTC. (SEQ. ID NO:38)

46. An oligonucleotide primer comprising a single strand of DNA which anneals to codons 104 to 110 of DPA transcript.

47. An oligonucleotide primer having the sequence GTCAATGTGGCAGATGAGGGT. (SEQ. ID NO:31)

92

48. An oligonucleotide primer having the sequence GCGGCTGGCACTTGAAAGCTC. (SEQ. ID NO:13)

49. An oligonucleotide primer having the sequence CCTGGGAGGGAAAACATTAC. (SEQ. ID NO:11)

50. An oligonucleotide primer having the sequence GTAGTTGTTGTCAGACAC. (SEQ. ID NO:12)

51. An oligonucleotide primer having the sequence CACGGTTCGGTAGCAGCGGAG. (SEQ. ID NO:14)

52. An oligonucleotide primer having the sequence CCTGGAGGGAAAACATTAC. (SEQ. ID NO:25)

53. An oligonucleotide primer having the sequence CTTGGAAACACCGTCACTTC. (SEQ. ID NO:33)

54. An oligonucleotide primer having the sequence GCCAGAACGCAGAGACTTAT. (SEQ. ID NO:40)

55. An oligonucleotide primer comprising a single strand of DNA which anneals to base pairs 18 to 38 of intron 3 of DRB loci.

56. An oligonucleotide primer having the sequence of GCCAAGAGTCGGCTCGCAGC. (SEQ. ID NO:20)

57. An oligonucleotide primer comprising a single strand of DNA which anneals to codons -4 to +3 of the DRB transcript.

58. An oligonucleotide primer having the sequence CTGGCCTTGGCTGGGACACC. (SEQ. ID NO:5)

93

59. An oligonucleotide primer comprising a single strand of DNA which anneals to codons 88 to 94 of the DPB transcript.

60. An oligonucleotide primer having the sequence TCCGCTCTTGAGGGTCCGCGC. (SEQ. ID NO:8)

61. An oligonucleotide primer comprising a single strand of DNA which anneals to codons 11 to 17 of the DQB transcript.

62. An oligonucleotide primer having the sequence of TTAAAGGGCATGTCCTACTTC. (SEQ. ID NO:9)

63. An oligonucleotide primer comprising a single strand of DNA which anneals to base pairs -42 to -62 of intron 2 of the DPB locus.

64. An oligonucleotide primer having the sequence AGAGGGAGAAAGGGATTAGA. (SEQ. ID NO:27)

65. An oligonucleotide primer comprising a single strand of DNA which anneals to intron 39 to 59 of intron 3 of the DPB gene.

66. An oligonucleotide primer having the sequence GCCCTGGCACGGCCGGGG. (SEQ. ID NO:28)

67. An oligonucleotide primer comprising a single strand of DNA which anneals to base pairs -69 to -50 of intron 2 of the DPB locus.

68. An oligonucleotide primer having the sequence CTCTAGCTTTGACCACTTGC. (SEQ. ID NO:35)

94

69. An oligonucleotide primer comprising a single strand of DNA which anneals to base pairs 55 to 71 of intron 3 of the DPB1 locus.

70. An oligonucleotide primer having the sequence AGTCAGGGTGGAGAGGG. (SEQ. ID NO:36)

71. An oligonucleotide primer comprising a single strand of DNA which anneals to codons 87 to 94 of the DRB transcript.

72. An oligonucleotide primer comprising a single strand of DNA which anneals to codons 38 to 45 of the DRB transcript.

73. An oligonucleotide primer having the sequence GCGCTTCGAGGGCACGGGG. (SEQ. ID NO:16)

74. An oligonucleotide primer having the sequence CGGCCAAAGGCCCTCACTCAC. (SEQ. ID NO:29)

75. An oligonucleotide primer having the sequence GGCTGTGAGCTGGTGGAAACG. (SEQ. ID NO:37)

76. An oligonucleotide primer having the sequence TACTGATGGTGCTGCTACAT. (SEQ. ID NO:26)

77. An oligonucleotide primer having the sequence CGCTCATGGCGCCCTCCC. (SEQ. ID NO:30)

78. An oligonucleotide primer having the sequence CTGCTGAGCTCCGGAGGCT. (SEQ. ID NO:34)

79. An oligonucleotide primer having the sequence AACTTGAAATAACCTtGAATCCAG. (SEQ. ID NO:41)

95

80. An oligonucleotide primer having the sequence ATGGGAGAGGTCACTGGG. (SEQ. ID NO:10)

81. An oligonucleotide primer having the sequence TACGGTCCCTGGCCAG. (SEQ. ID NO:15)

82. A method for rapid automated determination of major histocompatibility complex class genotype of a subject in a sample containing subject nucleic acid comprising:

- (a) isolating nucleic acid from said sample with an RNA/DNA extractor;
- (b) amplifying said nucleic acid by polymerase chain reaction using a thermocycler to generate a polymerase chain reaction product for each allele of each gene locus to be sequenced, all of said alleles for each gene locus and chromosome to be sequenced being amplified with at least one conserved oligonucleotide primer pair and at least one of said alleles for each gene locus and chromosome to be sequenced being amplified with at least one conserved oligonucleotide primer and one non-conserved oligonucleotide primer;
- (c) sequencing directly each polymerase chain reaction product for each allele at each gene locus of each chromosome in an automated sequencing apparatus with tag polymerase and a conserved primer specific for each locus to be sequenced; and
- (d) analyzing each sequenced polymerase chain reaction product to determine the genotype of said subject with a computer having a data base with allelic sequence information to compare the sequence of each allele of each gene locus

96

sequenced to known sequences for each such gene locus followed by comparing the sequence of each allele of each gene locus amplified with a conserved/non-conserved oligonucleotide primer pair to the nucleotide sequence of each allele of such gene locus amplified with a conserved oligonucleotide primer pair.

83. A method for determining the genotype at one or more polymorphic gene locus of a subject in a sample containing subject nucleic acid comprising:
  - (a) isolating nucleic acid from said sample;
  - (b) amplifying said nucleic acid by polymerase chain reaction to generate sufficient polymerase chain reaction product for each allele of said gene locus to be sequenced, all of said alleles for each gene locus and chromosome to be sequenced being amplified with at least one conserved oligonucleotide Primer pair and at least one of said alleles for each gene locus and chromosome to be sequenced being amplified with at least one conserved oligonucleotide primer and at least one non-conserved oligonucleotide primer;
  - (c) sequencing directly each polymerase chain reaction product for each allele at each gene locus of each chromosome with a sequencing enzyme and a conserved primer specific for each locus that is sequenced; and
  - (d) analyzing each sequenced polymerase chain reaction product to determine the genotype of said subject.
84. The method of claim 83 wherein said isolated nucleic acid is genomic DNA.

97

85. The method of claim 83 wherein said isolated nucleic acid is RNA and further comprises the following step prior to amplifying said nucleic acid:

- (a) synthesizing cDNA molecules for each allele of each gene locus to be sequenced, wherein said synthesis employs a locus-specific oligonucleotide primer that anneals to a conserved region of each allele of each said gene locus.

86. A method for rapid automated determination of the genotype at one or more polymorphic gene locus of a subject in a sample containing subject nucleic acid comprising:

- (a) isolating nucleic acid from said sample with an RNA/DNA extractor;
- (b) amplifying said nucleic acid by polymerase chain reaction using a thermocycler to generate a polymerase chain reaction product for each allele of each gene locus to be sequenced, all of said alleles for each gene locus and chromosome to be sequenced being amplified with at least one conserved oligonucleotide primer pair and at least one of said alleles for each gene locus and chromosome to be sequenced being amplified with at least one conserved oligonucleotide primer and one non-conserved oligonucleotide primer;
- (c) sequencing directly each polymerase chain reaction product for each allele at each gene locus of each chromosome in an automated sequencing apparatus with a sequencing enzyme and a conserved primer specific for each locus to be sequenced; and


98

- (d) analyzing each sequenced polymerase chain reaction product to determine the genotype of said subject with a computer having a data base with allelic sequence information to compare the sequence of each allele of each gene locus sequenced to known sequences for each such gene locus followed by comparing the sequence of each allele of each gene locus amplified with a conserved/non-conserved oligonucleotide primer pair to the nucleotide sequence of each allele of such gene locus amplified with a conserved oligonucleotide primer pair.

SUBSTITUTE SHEET

SUBSTITUTE SHEET

FIG. 1A




WO 92/15711

PCT/US92/01675

WO 92/15711

PCT/US92/01675

FIG. 1B



1/1

SUBSTITUTE SHEET

FIG. 2A  
3/




FIG. 2B

54

FORENSIC SAMPLES

| LOCI      | DRB  | DRB  | DRB  | DQB  | DQB | DPA |
|-----------|------|------|------|------|-----|-----|
| PRIMER #1 | 1406 | 1406 | 1406 | 1406 | 932 | 14  |
| PRIMER #2 | 22   | 23   | 23   | 24   | 931 | 10  |
| REACTION  | (S)  | (V)  | (T)  | (U)  | (W) | (X) |
|           |      |      |      |      |     | Y)  |

1  
SPIN-DIALYSIS

| LOCI<br>PRIMER #3 | SEQUENCING |      |      |      |     |     |
|-------------------|------------|------|------|------|-----|-----|
|                   | DRB        | DRB  | DRB  | DQB  | DPB | DPA |
|                   | 12         | 1400 | 1400 | 1400 | 5   | 16  |

# ELECTROPHORESIS | X-RAY FILM EXPOSURE

SUBSTITUTE SHEET

FIG. 3 *e*/2  
0201  
0302  
0401  
0501  
0101

|             |      |      |            |
|-------------|------|------|------------|
| DBBI * Q301 | DQBI | DRBI | DRBI / 3/4 |
| DBR3 * Q401 | GATC | GATC | GATC       |
| DBR4 * Q101 |      |      |            |
| DBB1 * Q302 |      |      |            |

|   |   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|---|
| T | T | T | C | A | T | G | A |
| C | T | C | A | A | T | G | A |
| T | C | C | A | A | T | G | C |
| A | G | G | A | A | T | G | C |

T A G G A A  
T G G G A A  
C O D O N 50  
\* \*

A A T C  
T C C T  
A A C A  
C O D O N 62

CODON 68  
A A A G  
A G A G

CODON 76

207 (69) 219 (69) 273 (79)

SUBSTITUTE SHEET

## INTERNATIONAL SEARCH REPORT

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)<sup>3</sup>  
According to International Patent Classification (IPC) or to both National Classification and IPC

IPC (5) : C12Q 1/68 ; C12P 19/34  
US CL. : 435/6, 91

## II. FIELDS SEARCHED

| Classification System | Minimum Documentation Searched*                                                                                                               | Classification Symbols |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| U.S.                  | Documentation Searched other than Minimum Documentation<br>to the extent that such Documents are included in the Fields Searched <sup>5</sup> |                        |

III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>14</sup>

| Category* | Citation of Document <sup>15</sup> with indication, where appropriate, of the relevant pages <sup>17</sup>                                                                                                      | Reference to Claim No. <sup>18</sup> |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|
| Y         | BIOCETIQUES, Volume 7, No. 4 issued April 1989, K.B. Gorman et al., "Simplified Method for Selective Amplification and Direct Sequencing of cDNAs", pages 326-329, see entire document.                         | 1-82                                 |
| Y         | IMMUNOGENETICS, Volume 31, issued March 1990, S.G.E. March et al., "HHA-DNA Nucleotide Sequences", 1990*, pages 141-144, see entire document.                                                                   | 1-82                                 |
| Y         | PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE USA, Volume 85, issued January 1988, D.R. Engelske et al., "Direct Sequencing of Enzymatically Amplified Human Genomic DNA", pages 544-548, see entire document. | 2                                    |
| Y         | CLINICAL CHEMISTRY, Volume 36 No. 11, issued November 1990, L.J. McBride et al., "Automated DNA Sequencing Methods Involving Polymerase Chain Reaction", pages 2196-2201, see especially pages 2200-2201.       | 92                                   |

\* Special categories of cited documents:<sup>16</sup>  
"A" document defining the general state of the art which is not considered to be of particular relevance  
"B" earlier document, but published on or after the international filing date  
"C" document which may throw doubt on priority (date) or which is cited to establish the authenticity of another claim or other special reason (see Article 55(3) of the Convention)  
"D" document referring to an oral disclosure, use, exhibition or other means  
"E" document published prior to the international filing date but later than the priority date claimed  
"F" document published after the international filing date and not in conflict with the application but which it is necessary to understand the principle or scope of the invention  
"G" document which may be relied upon as evidence of ownership or right to file the application  
"H" document which may throw doubt on the validity of the application or which is cited to establish the priority of another application or other special reason (see Article 55(3) of the Convention)  
"I" document which may be relied upon as evidence of ownership or right to file the application  
"J" document which may be relied upon as evidence of ownership or right to file the application  
"K" document which may be relied upon as evidence of ownership or right to file the application  
"L" document which may be relied upon as evidence of ownership or right to file the application  
"M" document which may be relied upon as evidence of ownership or right to file the application  
"N" document which may be relied upon as evidence of ownership or right to file the application  
"O" document which may be relied upon as evidence of ownership or right to file the application  
"P" document which may be relied upon as evidence of ownership or right to file the application  
"Q" document which may be relied upon as evidence of ownership or right to file the application  
"R" document which may be relied upon as evidence of ownership or right to file the application  
"S" document which may be relied upon as evidence of ownership or right to file the application  
"T" document which may be relied upon as evidence of ownership or right to file the application  
"U" document which may be relied upon as evidence of ownership or right to file the application  
"V" document which may be relied upon as evidence of ownership or right to file the application  
"W" document which may be relied upon as evidence of ownership or right to file the application  
"X" document which may be relied upon as evidence of ownership or right to file the application  
"Y" document which may be relied upon as evidence of ownership or right to file the application  
"Z" document which may be relied upon as evidence of ownership or right to file the application

| Date of the Actual Completion of the International Search <sup>2</sup> | Date of Mailing of this International Search Report <sup>2</sup> |
|------------------------------------------------------------------------|------------------------------------------------------------------|
| 29 May 1992                                                            | 05 JUN 1992                                                      |

International Searching Authority<sup>1</sup> : ISA/US  
Signature of Authorized Officer<sup>2</sup> : *J. M. Mcbride*  
REBECCA PROUTY

Form PCTISA/210 (second sheet)(May 1986) B

210(70)  
DDRB16  
DRB17  
DRB18  
DRB19  
DRB20  
DRB21  
DRB22  
DRB23  
DRB24  
DRB25  
DRB26  
DRB27  
DRB28  
DRB29  
DRB30  
DRB31  
DRB32  
DRB33  
DRB34  
DRB35  
DRB36  
DRB37  
DRB38  
DRB39  
DRB40  
DRB41  
DRB42  
DRB43  
DRB44  
DRB45  
DRB46  
DRB47  
DRB48  
DRB49  
DRB50  
DRB51  
DRB52  
DRB53  
DRB54  
DRB55  
DRB56  
DRB57  
DRB58  
DRB59  
DRB60  
DRB61  
DRB62  
DRB63  
DRB64  
DRB65  
DRB66  
DRB67  
DRB68  
DRB69  
DRB70  
DRB71  
DRB72  
DRB73  
DRB74  
DRB75  
DRB76  
DRB77  
DRB78  
DRB79  
DRB80  
DRB81  
DRB82  
DRB83  
DRB84  
DRB85  
DRB86  
DRB87  
DRB88  
DRB89  
DRB90  
DRB91  
DRB92  
DRB93  
DRB94  
DRB95  
DRB96  
DRB97  
DRB98  
DRB99  
DRB100  
DRB101  
DRB102  
DRB103  
DRB104  
DRB105  
DRB106  
DRB107  
DRB108  
DRB109  
DRB110  
DRB111  
DRB112  
DRB113  
DRB114  
DRB115  
DRB116  
DRB117  
DRB118  
DRB119  
DRB120  
DRB121  
DRB122  
DRB123  
DRB124  
DRB125  
DRB126  
DRB127  
DRB128  
DRB129  
DRB130  
DRB131  
DRB132  
DRB133  
DRB134  
DRB135  
DRB136  
DRB137  
DRB138  
DRB139  
DRB140  
DRB141  
DRB142  
DRB143  
DRB144  
DRB145  
DRB146  
DRB147  
DRB148  
DRB149  
DRB150  
DRB151  
DRB152  
DRB153  
DRB154  
DRB155  
DRB156  
DRB157  
DRB158  
DRB159  
DRB160  
DRB161  
DRB162  
DRB163  
DRB164  
DRB165  
DRB166  
DRB167  
DRB168  
DRB169  
DRB170  
DRB171  
DRB172  
DRB173  
DRB174  
DRB175  
DRB176  
DRB177  
DRB178  
DRB179  
DRB180  
DRB181  
DRB182  
DRB183  
DRB184  
DRB185  
DRB186  
DRB187  
DRB188  
DRB189  
DRB190  
DRB191  
DRB192  
DRB193  
DRB194  
DRB195  
DRB196  
DRB197  
DRB198  
DRB199  
DRB200  
DRB201  
DRB202  
DRB203  
DRB204  
DRB205  
DRB206  
DRB207  
DRB208  
DRB209  
DRB210  
DRB211  
DRB212  
DRB213  
DRB214  
DRB215  
DRB216  
DRB217  
DRB218  
DRB219  
DRB220  
DRB221  
DRB222  
DRB223  
DRB224  
DRB225  
DRB226  
DRB227  
DRB228  
DRB229  
DRB230  
DRB231  
DRB232  
DRB233  
DRB234  
DRB235  
DRB236  
DRB237  
DRB238  
DRB239  
DRB240  
DRB241  
DRB242  
DRB243  
DRB244  
DRB245  
DRB246  
DRB247  
DRB248  
DRB249  
DRB250  
DRB251  
DRB252  
DRB253  
DRB254  
DRB255  
DRB256  
DRB257  
DRB258  
DRB259  
DRB260  
DRB261  
DRB262  
DRB263  
DRB264  
DRB265  
DRB266  
DRB267  
DRB268  
DRB269  
DRB270  
DRB271  
DRB272  
DRB273  
DRB274  
DRB275  
DRB276  
DRB277  
DRB278  
DRB279  
DRB280  
DRB281  
DRB282  
DRB283  
DRB284  
DRB285  
DRB286  
DRB287  
DRB288  
DRB289  
DRB290  
DRB291  
DRB292  
DRB293  
DRB294  
DRB295  
DRB296  
DRB297  
DRB298  
DRB299  
DRB300  
DRB301  
DRB302  
DRB303  
DRB304  
DRB305  
DRB306  
DRB307  
DRB308  
DRB309  
DRB310  
DRB311  
DRB312  
DRB313  
DRB314  
DRB315  
DRB316  
DRB317  
DRB318  
DRB319  
DRB320  
DRB321  
DRB322  
DRB323  
DRB324  
DRB325  
DRB326  
DRB327  
DRB328  
DRB329  
DRB330  
DRB331  
DRB332  
DRB333  
DRB334  
DRB335  
DRB336  
DRB337  
DRB338  
DRB339  
DRB340  
DRB341  
DRB342  
DRB343  
DRB344  
DRB345  
DRB346  
DRB347  
DRB348  
DRB349  
DRB350  
DRB351  
DRB352  
DRB353  
DRB354  
DRB355  
DRB356  
DRB357  
DRB358  
DRB359  
DRB360  
DRB361  
DRB362  
DRB363  
DRB364  
DRB365  
DRB366  
DRB367  
DRB368  
DRB369  
DRB370  
DRB371  
DRB372  
DRB373  
DRB374  
DRB375  
DRB376  
DRB377  
DRB378  
DRB379  
DRB380  
DRB381  
DRB382  
DRB383  
DRB384  
DRB385  
DRB386  
DRB387  
DRB388  
DRB389  
DRB390  
DRB391  
DRB392  
DRB393  
DRB394  
DRB395  
DRB396  
DRB397  
DRB398  
DRB399  
DRB400  
DRB401  
DRB402  
DRB403  
DRB404  
DRB405  
DRB406  
DRB407  
DRB408  
DRB409  
DRB410  
DRB411  
DRB412  
DRB413  
DRB414  
DRB415  
DRB416  
DRB417  
DRB418  
DRB419  
DRB420  
DRB421  
DRB422  
DRB423  
DRB424  
DRB425  
DRB426  
DRB427  
DRB428  
DRB429  
DRB430  
DRB431  
DRB432  
DRB433  
DRB434  
DRB435  
DRB436  
DRB437  
DRB438  
DRB439  
DRB440  
DRB441  
DRB442  
DRB443  
DRB444  
DRB445  
DRB446  
DRB447  
DRB448  
DRB449  
DRB450  
DRB451  
DRB452  
DRB453  
DRB454  
DRB455  
DRB456  
DRB457  
DRB458  
DRB459  
DRB460  
DRB461  
DRB462  
DRB463  
DRB464  
DRB465  
DRB466  
DRB467  
DRB468  
DRB469  
DRB470  
DRB471  
DRB472  
DRB473  
DRB474  
DRB475  
DRB476  
DRB477  
DRB478  
DRB479  
DRB480  
DRB481  
DRB482  
DRB483  
DRB484  
DRB485  
DRB486  
DRB487  
DRB488  
DRB489  
DRB490  
DRB491  
DRB492  
DRB493  
DRB494  
DRB495  
DRB496  
DRB497  
DRB498  
DRB499  
DRB500  
DRB501  
DRB502  
DRB503  
DRB504  
DRB505  
DRB506  
DRB507  
DRB508  
DRB509  
DRB510  
DRB511  
DRB512  
DRB513  
DRB514  
DRB515  
DRB516  
DRB517  
DRB518  
DRB519  
DRB520  
DRB521  
DRB522  
DRB523  
DRB524  
DRB525  
DRB526  
DRB527  
DRB528  
DRB529  
DRB530  
DRB531  
DRB532  
DRB533  
DRB534  
DRB535  
DRB536  
DRB537  
DRB538  
DRB539  
DRB540  
DRB541  
DRB542  
DRB543  
DRB544  
DRB545  
DRB546  
DRB547  
DRB548  
DRB549  
DRB550  
DRB551  
DRB552  
DRB553  
DRB554  
DRB555  
DRB556  
DRB557  
DRB558  
DRB559  
DRB560  
DRB561  
DRB562  
DRB563  
DRB564  
DRB565  
DRB566  
DRB567  
DRB568  
DRB569  
DRB570  
DRB571  
DRB572  
DRB573  
DRB574  
DRB575  
DRB576  
DRB577  
DRB578  
DRB579  
DRB580  
DRB581  
DRB582  
DRB583  
DRB584  
DRB585  
DRB586  
DRB587  
DRB588  
DRB589  
DRB590  
DRB591  
DRB592  
DRB593  
DRB594  
DRB595  
DRB596  
DRB597  
DRB598  
DRB599  
DRB600  
DRB601  
DRB602  
DRB603  
DRB604  
DRB605  
DRB606  
DRB607  
DRB608  
DRB609  
DRB610  
DRB611  
DRB612  
DRB613  
DRB614  
DRB615  
DRB616  
DRB617  
DRB618  
DRB619  
DRB620  
DRB621  
DRB622  
DRB623  
DRB624  
DRB625  
DRB626  
DRB627  
DRB628  
DRB629  
DRB630  
DRB631  
DRB632  
DRB633  
DRB634  
DRB635  
DRB636  
DRB637  
DRB638  
DRB639  
DRB640  
DRB641  
DRB642  
DRB643  
DRB644  
DRB645  
DRB646  
DRB647  
DRB648  
DRB649  
DRB650  
DRB651  
DRB652  
DRB653  
DRB654  
DRB655  
DRB656  
DRB657  
DRB658  
DRB659  
DRB660  
DRB661  
DRB662  
DRB663  
DRB664  
DRB665  
DRB666  
DRB667  
DRB668  
DRB669  
DRB670  
DRB671  
DRB672  
DRB673  
DRB674  
DRB675  
DRB676  
DRB677  
DRB678  
DRB679  
DRB680  
DRB681  
DRB682  
DRB683  
DRB684  
DRB685  
DRB686  
DRB687  
DRB688  
DRB689  
DRB690  
DRB691  
DRB692  
DRB693  
DRB694  
DRB695  
DRB696  
DRB697  
DRB698  
DRB699  
DRB700  
DRB701  
DRB702  
DRB703  
DRB704  
DRB705  
DRB706  
DRB707  
DRB708  
DRB709  
DRB710  
DRB711  
DRB712  
DRB713  
DRB714  
DRB715  
DRB716  
DRB717  
DRB718  
DRB719  
DRB720  
DRB721  
DRB722  
DRB723  
DRB724  
DRB725  
DRB726  
DRB727  
DRB728  
DRB729  
DRB730  
DRB731  
DRB732  
DRB733  
DRB734  
DRB735  
DRB736  
DRB737  
DRB738  
DRB739  
DRB740  
DRB741  
DRB742  
DRB743  
DRB744  
DRB745  
DRB746  
DRB747  
DRB748  
DRB749  
DRB750  
DRB751  
DRB752  
DRB753  
DRB754  
DRB755  
DRB756  
DRB757  
DRB758  
DRB759  
DRB760  
DRB761  
DRB762  
DRB763  
DRB764  
DRB765  
DRB766  
DRB767  
DRB768  
DRB769  
DRB770  
DRB771  
DRB772  
DRB773  
DRB774  
DRB775  
DRB776  
DRB777  
DRB778  
DRB779  
DRB780  
DRB781  
DRB782  
DRB783  
DRB784  
DRB785  
DRB786  
DRB787  
DRB788  
DRB789  
DRB790  
DRB791  
DRB792  
DRB793  
DRB794  
DRB795  
DRB796  
DRB797  
DRB798  
DRB799  
DRB800  
DRB801  
DRB802  
DRB803  
DRB804  
DRB805  
DRB806  
DRB807  
DRB808  
DRB809  
DRB810  
DRB811  
DRB812  
DRB813  
DRB814  
DRB815  
DRB816  
DRB817  
DRB818  
DRB819  
DRB820  
DRB821  
DRB822  
DRB823  
DRB824  
DRB825  
DRB826  
DRB827  
DRB828  
DRB829  
DRB830  
DRB831  
DRB832  
DRB833  
DRB834  
DRB835  
DRB836  
DRB837  
DRB838  
DRB839  
DRB840  
DRB841  
DRB842  
DRB843  
DRB844  
DRB845  
DRB846  
DRB847  
DRB848  
DRB849  
DRB850  
DRB851  
DRB852  
DRB853  
DRB854  
DRB855  
DRB856  
DRB857  
DRB858  
DRB859  
DRB860  
DRB861  
DRB862  
DRB863  
DRB864  
DRB865  
DRB866  
DRB867  
DRB868  
DRB869  
DRB870  
DRB871  
DRB872  
DRB873  
DRB874  
DRB875  
DRB876  
DRB877  
DRB878  
DRB879  
DRB880  
DRB881  
DRB882  
DRB883  
DRB884  
DRB885  
DRB886  
DRB887  
DRB888  
DRB889  
DRB890  
DRB891  
DRB892  
DRB893  
DRB894  
DRB895  
DRB896  
DRB897  
DRB898  
DRB899  
DRB900  
DRB901  
DRB902  
DRB903  
DRB904  
DRB905  
DRB906  
DRB907  
DRB908  
DRB909  
DRB910  
DRB911  
DRB912  
DRB913  
DRB914  
DRB915  
DRB916  
DRB917  
DRB918  
DRB919  
DRB920  
DRB921  
DRB922  
DRB923  
DRB924  
DRB925  
DRB926  
DRB927  
DRB928  
DRB929  
DRB930  
DRB931  
DRB932  
DRB933  
DRB934  
DRB935  
DRB936  
DRB937  
DRB938  
DRB939  
DRB940  
DRB941  
DRB942  
DRB943  
DRB944  
DRB945  
DRB946  
DRB947  
DRB948  
DRB949  
DRB950  
DRB951  
DRB952  
DRB953  
DRB954  
DRB955  
DRB956  
DRB957  
DRB958  
DRB959  
DRB960  
DRB961  
DRB962  
DRB963  
DRB964  
DRB965  
DRB966  
DRB967  
DRB968  
DRB969  
DRB970  
DRB971  
DRB972  
DRB973  
DRB974  
DRB975  
DRB976  
DRB977  
DRB978  
DRB979  
DRB980  
DRB981  
DRB982  
DRB983  
DRB984  
DRB985  
DRB986  
DRB987  
DRB988  
DRB989  
DRB990  
DRB991  
DRB992  
DRB993  
DRB994  
DRB995  
DRB996  
DRB997  
DRB998  
DRB999  
DRB1000  
DRB1001  
DRB1002  
DRB1003  
DRB1004  
DRB1005  
DRB1006  
DRB1007  
DRB1008  
DRB1009  
DRB10010  
DRB10011  
DRB10012  
DRB10013  
DRB10014  
DRB10015  
DRB10016  
DRB10017  
DRB10018  
DRB10019  
DRB10020  
DRB10021  
DRB10022  
DRB10023  
DRB10024  
DRB10025  
DRB10026  
DRB10027  
DRB10028  
DRB10029  
DRB10030  
DRB10031  
DRB10032  
DRB10033  
DRB10034  
DRB10035  
DRB10036  
DRB10037  
DRB10038  
DRB10039  
DRB10040  
DRB10041  
DRB10042  
DRB10043  
DRB10044  
DRB10045  
DRB10046  
DRB10047  
DRB10048  
DRB10049  
DRB10050  
DRB10051  
DRB10052  
DRB10053  
DRB10054  
DRB10055  
DRB10056  
DRB10057  
DRB10058  
DRB10059  
DRB10060  
DRB10061  
DRB10062  
DRB10063  
DRB10064  
DRB10065  
DRB10066  
DRB10067  
DRB10068  
DRB10069  
DRB10070  
DRB10071  
DRB10072  
DRB10073  
DRB10074  
DRB10075  
DRB10076  
DRB10077  
DRB10078  
DRB10079  
DRB10080  
DRB10081  
DRB10082  
DRB10083  
DRB10084  
DRB10085  
DRB10086  
DRB10087  
DRB10088  
DRB10089  
DRB10090  
DRB10091  
DRB10092  
DRB10093  
DRB10094  
DRB10095  
DRB10096  
DRB10097  
DRB10098  
DRB10099  
DRB100100  
DRB100101  
DRB100102  
DRB100103  
DRB100104  
DRB100105  
DRB100106  
DRB100107  
DRB100108  
DRB100109  
DRB100110  
DRB100111  
DRB100112  
DRB100113  
DRB100114  
DRB100115  
DRB100116  
DRB100117  
DRB100118  
DRB100119  
DRB100120  
DRB100121  
DRB100122  
DRB100123  
DRB100124  
DRB100125  
DRB100126  
DRB100127  
DRB100128  
DRB100129  
DRB100130  
DRB100131  
DRB100132  
DRB100133  
DRB100134  
DRB100135  
DRB100136  
DRB100137  
DRB100138  
DRB100139  
DRB100140  
DRB100141  
DRB100142  
DRB100143  
DRB100144  
DRB100145  
DRB100146  
DRB100147  
DRB100148  
DRB100149  
DRB100150  
DRB100151  
DRB100152  
DRB100153  
DRB100154  
DRB100155  
DRB100156  
DRB100157  
DRB100158  
DRB100159  
DRB100160  
DRB100161  
DRB100162  
DRB100163  
DRB100164  
DRB100165  
DRB100166  
DRB100167  
DRB100168  
DRB100169  
DRB100170  
DRB100171  
DRB100172  
DRB100173  
DRB100174  
DRB100175  
DRB100176  
DRB100177  
DRB100178  
DRB100179  
DRB100180  
DRB100181  
DRB100182  
DRB100183  
DRB100184  
DRB100185  
DRB100186  
DRB100187  
DRB100188  
DRB100189  
DRB100190  
DRB100191  
DRB100192  
DRB100193  
DRB100194  
DRB100195  
DRB100196  
DRB100197  
DRB100198  
DRB100199  
DRB100200  
DRB100201  
DRB100202  
DRB100203  
DRB100204  
DRB100205  
DRB100206  
DRB100207  
DRB100208  
DRB100209  
DRB100210  
DRB100211  
DRB100212  
DRB100213  
DRB100214  
DRB100215  
DRB100216  
DRB100217  
DRB100218  
DRB100219  
DRB100220  
DRB100221  
DRB100222  
DRB100223  
DRB100224  
DRB100225  
DRB100226  
DRB100227  
DRB100228  
DRB100229  
DRB100230  
DRB100231  
DRB100232  
DRB100233  
DRB100234  
DRB100235  
DRB100236  
DRB100237<br